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THE ROLE OF AUTOPHAGY IN THE SENSITIVITY OF OSTEOSARCOMA CELLS
TO GEMCITABINE TREATMENT
Janice M. Santiago-O’Farrill, MS
Supervisory Professor: Eugenie S. Kleinerman, MD
Despite treatment improvement for osteosarcoma (OS), overall survival has
remained unchanged in the last 20 years. Pulmonary metastasis continues to be the
main cause of death; novel therapeutic strategies are urgently needed to improve the
survival rate of these patients. Previous data in our laboratory has demonstrated that
aerosol gemcitabine (GCB) treatment has a significant therapeutic effect on metastatic
OS. However, treatment efficacy is decreased due to acquired resistance by a
population of tumor cells that fails to respond to treatment. Recent studies have
implicated autophagy as a resistance mechanism in various types of cancer. The
purpose of this study was to determine whether the process of autophagy plays a role
in protecting OS cells from the cytotoxic effects of GCB, allowing them to survive and
avoid drug-induced cell death.
We first evaluated the ability of GCB to induce autophagy using a panel of OS
cells. Following GCB treatment Acridine orange staining revealed the formation of
acidic vesicular organelles (AVOs), a hallmark of autophagy. Western blot analysis
showed an increase in several autophagy markers including; increased conversion of
microtubule-associated light chain 3 (LC3I/LC3II), increased Beclin expression and a
decrease in p62/SQSTM1 protein expression. Formation of autophagic vacuoles was
also demonstrated using electron microscopy. These results confirm that autophagy
was induced following GCB treatment. Furthermore, western blot analysis and kinase
vi

array assays demonstrated that GCB treatment decrease the phosphorylation of AKT,
mTOR, p70S6K and PRAS40, suggesting that this signaling pathway is involved in the
induction of autophagy by GCB.
To test whether autophagy contributes to the resistance of OS cells to GCB, we
determined the impact of autophagy inhibition on the sensitivity of OS cells to GCB.
Autophagy inhibition by either the pharmacologic inhibitor Hydroxychloroquine or
genetic inhibition of BECN and ATG5 resulted in either increased or decreased
sensitivity of OS cells to gemcitabine depending on the cell line tested. Specifically, the
sensitivity of LM7 cells to GCB was greatly enhanced after autophagy inhibition,
suggesting autophagy as a cytoprotective mechanism. However, inhibition of
autophagy in CCH-OS-D and K7M3 cells decreased cell sensitivity to GCB, suggesting
that GCB-induced autophagy contributed to cell death.
A more thorough understanding of the molecular pathways that govern the
autophagy process may allow the identification of a biologic marker that can predict
whether autophagy function to inhibit or promote GCB-induced cytotoxicity. Our
preliminary data showed that phosphorylation of Heat Shock Protein 27 (HSP27)
correlated with autophagy as a mechanism of cellular resistance in different OS cell
lines. Taken together, these results suggest that GCB induces autophagy in OS cells
through the AKT/mTOR pathway and that when HSP27 is induced inhibition of
autophagy will increase sensitivity to GCB.
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Chapter 1: Introduction
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Osteosarcoma
Osteosarcoma (OS) is the most common type of pediatric bone cancer with
approximately 400 new cases diagnosed per year in the United States. It is
characterized by formation of immature bone or defective osteoids by tumor cells [1].
OS mainly affects children and adolescents between the ages of 10-25, and also
patients over the age of 50 [1, 2]. The most common sites of occurrence are in the
metaphysis of long bones and rapid growth areas such as the knees, femur, tibia and
humerus [1-3]. OS is a highly aggressive tumor with a tendency to spread to other
organs, with the lungs as the most common site of metastasis [2, 4]. OS diagnosis is
based on x-rays, x-ray computed tomography (X-ray CT), magnetic resonance imaging
(MRI), and positron emission tomography (PET) scan [1].
unknown.

The etiology of OS is

Studies have identified some epidemiologic, environmental and genetic

causes associated with OS including ionizing radiation, alkylating agents, mutations in
the retinoblastoma gene (RB), Li-Fraumeni syndrome (deletion in p53), Paget’s disease
(bone dysplasia), Rothmund-Thomson syndrome (mutation in RECQL4 gene) and
Wermer Syndrome (mutation in the WRN ,RECQL3, gene) [1, 4, 5].

Available treatment options for Osteosarcoma
In the 1960s, treatment of OS consisted of surgical excision of all detectable
disease [3]. However, despite good control of the primary tumor, most patients recurred
with metastatic lung disease [3]. Since surgery alone is not effective for OS, the current
therapeutic strategies consist of pre-operative chemotherapy followed by surgery, and
then post-operative chemotherapy. Limb-salvage is the most common type of surgery
for bone sarcoma treatment [3]. Chemotherapy includes high-dose methotrexate
2

(HDMTX), leucovorin, doxorobucin, cisplatin and ifosfamide, and has increased the 5year survival rate of patients with localized disease from 20% to approximately 70%
(See Table 1) [1, 3].
Lung metastases represent the main cause of death of OS patients [3]. With the
introduction of adjuvant therapy, the survival rate in patients with non-metastatic
disease has significantly improved. However, in patients with pulmonary metastasis,
little improvement has been observed and 5-year survival rate remain low at merely
25%-30% [3]. Thus, new strategies targeting primary osteosarcoma and lung
metastasis are urgently needed.

Table 1. Current chemotherapy agents in OS [3, 4]
Surgery
Limb-Salvage Remove the tumor and part of the surrounding tissue but
(Gold standard) preserve limb function.
Chemotherapy
Mechanism of Action
Methotrexate Folate anti-metabolite. Inhibits the function of dihydrofolate
(MTX)
reductase, resulting in folic acid deficiency and cell death.
Leucovorin

Reduced folic acid. Used in combination with MTX to help
decrease side effects.

Doxorobucin
(Adriamycin)

Intercalates into the DNA and inhibits the function of
Topoisomerase II stopping the process of transcription and
replication.

Cisplatin

Forms intra-strand and inter-strands crosslinks with DNA and
affects replication.

Ifosfamide

Analogue of cyclophosphamide and a nitrogen mustard-like
alkylating agent. Crosslinks and inhibits the synthesis of
DNA.

3

Emerging Therapies
Due to the lack of advancement in extending the survival rate of OS patients in the
last 20 years; several groups are attempting to discover new therapeutic approaches.
Some studies are focusing on testing immune system modulation strategies. For
example, Kleinerman and colleagues

demonstrated that the addition of Liposomal

Muramyl Tripeptide (L-MTP-PE) to the therapeutic regimen targets and activates
monocytes and macrophages, stimulating the immune system, resulting in the
prolongation of relapse time among osteosarcoma patients [1, 6, 7]. L-MTP-PE has
been approved by the European Union for the treatment of non-metastatic OS [8].
Additionally, there are ongoing clinical studies for the development of new small
molecules that specifically target intracellular signaling pathways. The Sarcoma
Alliance for Research through Collaboration (SARC) in conjunction with the Global
Cooperative Network (GCN) is conducting a phase II clinical trial with saracatinib, a Src
(tyrosine kinase involved in tumor cell motility and invasion) inhibitor, in OS patients
with metastatic disease [3]. Preclinical work is also investigating the effectiveness of
several mTOR inhibitors. mTOR is a serine-threonine kinase involved in regulation of
protein synthesis, it has been related to metastatic OS and poor prognosis [1, 9, 10].
Combination of sorafenib and everolimus has exhibited complete inhibition of both
mTORC1 and mTORC2 [3, 11]. Grignani et. al., reported that the combination of these
two agents displayed some effect in a study of 38 patients with relapsed and nonresectable high-degree OS [12] .
Bisphosphonates, which inhibits the bone resorption of osteoclast, have been
considered as a new therapeutic approach for OS [3]. To date, Zolendronate is being

4

tested in two different ongoing clinical trials for OS treatment, with the aim to determine
optimal dose and disease-free survival, respectively.

Gemcitabine
Gemcitabine (GCB) (2’-Deoxy-2’,2’-difluorocytidine, dFdC or GCBdFdC) is a
deoxycytidine analogue that has been shown to have a broad range of antitumor
effects in various types of tumors including pancreatic cancer, breast cancer, ovarian
cancer and lung cancer [13-16]. GCB has three different mechanisms of action: 1)
incorporates into the DNA and inhibits DNA synthesis; 2) prevents DNA repair and 3)
through the inhibition of Ribonucleotide Reductase [17].
GCB is a pro-drug that once incorporated into the cell membrane by nucleoside
transporters is phosphorylated by deoxicytidine kinase (DCK) to GCB monophosphate
and then subsequently phosphorylated to GCB diphosphate (dFdCDP) and GCB
triphosphate (dFdCTP) by nucleoside monophosphate and diphosphate kinase,
respectively (Figure 2) [17]. dFdCTP incorporates into the DNA and interferes with DNA
synthesis and cell growth, causing cell death.
A second mechanism of action for GCB that has been identified is termed “masked
chain termination”. GCB being a nucleoside analogue is incorporated at the end of an
elongating DNA strand, after which one more deoxunucleotide is added, thus ending
the DNA strand. This process effectively locks the drug into the DNA chain as the
exonucleases that edit DNA polymerization are unable to remove the GCB nucleotide
from this specific position, preventing DNA repair [17].
GCB possesses a third mechanism of action. Through accumulation of dFdCDP,
the action Ribonucleotide Reductase enzyme is inhibited, the levels of deoxycytidine
5

triphosphate (dCTP) are decreased; dCTP is involved in the inhibition of DCK (which
phosphorylates GCB). Therefore, decreased cellular levels of dCTP results in GCB
self-potentiation and incorporation into the

DNA [17]. GCB also perpetuates its

cytotoxic activity by inhibiting deoxycytidine monophosphate deaminase, which is
involved in GCB degradation.
Preclinical studies in our laboratory have had success with the use of aerosol GCB
in the treatment of metastatic OS lung disease. Decrease in both primary tumor and
OS lung metastasis suggest GCB aerosol as a potential new treatment option [18, 19].
However, the efficacy of this drug in the treatment of OS lung metastasis is decreased
by the acquired resistance of some OS cells to treatment, suggested by the residual
tumors after treatment.

6

Figure 1. Molecular structure of Gemcitabine. (A) GCB (Gemzar; Eli Lilly and
Company) is categorized as a nucleoside analogue with the hydrogen atoms on the 2’
carbon of deoxycytidine are replaced by fluorine atoms. Adapted from
pubchem.ncbi.nlm.nih.gov

7

Figure 2. Mechanism of action of Gemcitabine. GCB is transported into the cell
membrane by nucleoside transporters. Following influx into the cell, GCB must be
phosphorylated by deoxycytidine kinase and converted into GCB monophosphate
(dFdCMP). It is then phosphorylated to the active GCB diphosphate (dFdCDP) and
GCB triphosphate (dFdCTP) by other kinases. The active form of GCB is then
accumulated in the cells and incorporated into the DNA, leading to inhibition of DNA
synthesis.
8

Autophagy
One of the major challenges in cancer treatment is acquired resistance by
cancer cells to chemotherapy. Therefore, there is an increased interest in determining
the molecular mechanisms implicated in cancer cell resistance to chemotherapy.
Autophagy has been described in several cancers as a protective mechanism and thus
it has recently become one of the most studied cell mechanisms in the cancer research
community.
Autophagy, a Greek word derived from Auto or “self” and phagy or “eating” was
coined by Christian de Duve in 1963 [20]. It is a catabolic mechanism that delivers
unwanted cytoplasmic components such as long-lived proteins and damaged
organelles to the lysosomes for degradation. Autophagy is activated as a defense
mechanism in response to adverse conditions and a variety of stressors such as
nutrient deprivation, hypoxia and cytotoxic effects, to promote cell survival [2, 21].
Even though studies have suggested that autophagy enhances cell survival, it also, at
high levels, can lead to cell death, recognized as autophagic cell death or programmed
cell death (PCD) type II [21].
There are three different types of autophagy that has been described based on
the mechanism by which the material is delivered to the lysosome; they are: 1) microautophagy, 2) chaperone-mediated autophagy (CMA) and 3) macro-autophagy [22,
23].
Microautophagy entails the direct engulfment of cytoplasmic material into the
lysosome. Cellular content is sequestered into the lysosome through invagination of the
lysosomal membrane [20, 23].

9

CMA is a process where cytosolic proteins that carry the KFERQ pentapeptide
motif are recognized by a chaperone, such as heat shock protein 70 (HSP70). This
facilitates the delivery of the protein to the lysosomal membrane protein 2A (LAMP2A),
which functions as a receptor in the lysosomal membrane and aids the translocation of
the protein into the lysosome for degradation [20, 23].
Macroautophagy (hereafter referred as autophagy) is the most studied type of
autophagy. It refers to an evolutionary conserved process that maintains cellular
homeostasis through turnover and degradation of unwanted/damaged proteins and
organelles. The cellular material is delivered into double membrane vesicles, called
autophagosomes. The autophagosome then fuses with the lysosomes to form the
autophagolysosomes, where the sequestered material is degraded by hydrolases
(Figure 5). The degradation of this material produces amino acids and fatty acids that
provide energy to the cell [23-25].

Molecular mechanism of autophagy
The process of autophagy comprises several steps that are regulated by more
than 30 autophagy related genes (ATGs). These steps are divided into; induction,
nucleation, elongation, maturation of the autophagosome, autophagosome-lysosome
fusion and degradation (Figure 5) [26].

Phagophore Formation
The process of autophagy is initiated by the formation of the phagophore.
Although the origin of the phagophore is not completely understood, it is thought that it
is derived from endoplasmic reticulum, trans-Golgi and endosomes [20].Formation of
10

the phagophore in yeast is regulated by the ATG1/ATG13/ATG17 complex [20, 26]. In
mammals, it requires the ULK1, ULK2 (unc-51-like kinase), mATG13 and FIP200 (focal
adhesion kinase family –interacting protein of 200 kDa) complex. This complex is
regulated by mTOR (Figure 3). Under stressful conditions, such as nutrient deprivation,
mTORC1 dissociates from the ULK1/2 complex. This leads to partial dephosphorylation
and activation of ULK1/2, mATG13 and FIP200, resulting in the activation and
localization of the ULK complex to the phagophore and triggering of the downstream
events that induce autophagy [20, 26].

ULK Complex
Normal
Conditions

P

P

P

P
ATG13

ATG13

mTORC1

Stress
Conditions

FIP200

FIP200

mTORC1

ULK1/2

ULK1/2

P
P

P

Blocks Induction of
autophagy

Induction of autophagy

Figure 3. Regulation of the ULK1 complex by mTOR. Under normal
conditions mTORC1 interacts with and phosphorylates ULK1/2 and ATG13. Under
stressful conditions, mTORC1 is released from the complex, ULK1/2 is
dephosphorylated and activated, which subsequently induces ULK to phosphorylate
ATG13, FIP200 and itself, leading to induction of autophagy.
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Class III phosphatidylinositol 3 kinase (PI3K) complex
The Class III phosphatidylinositol 3-kinase (PI3K) complex consists of the PI3K
protein, Vps34, Beclin and p150 and ATG14/Barkor. Once Vps34 is activated it
produces phosphatidylinositol-3-phosphate (PI-3P) [20]. This molecule is incorporated
into the autophagosome and although its precise role is still unclear, it is suggested to
be required for nucleation of the phagophore and recruitment of other ATGs [19].
Studies have reported additional regulators and binding partners of Beclin such as the
ultraviolet (UV) radiation resistance-associated gene (UVRAG), AMBRA and Bif-1 that
can also be part of the complex and positively regulate the formation of the phagophore
[20]. The phagophore expands and recruits cytoplasmic proteins and organelles, thus
sequestering the cargo in a double membrane called the autophagosome.

Elongation and autophagosome formation
The next step involves the formation and elongation of the phagophore
membrane. There are two essential ubiquitin-like conjugation complexes involved in the
formation of the autophagosome: the ATG12-ATG5 complex and the LC3-PE complex
(Figure 4) [20, 26].

ATG12-ATG5 Complex
The formation of the first complex requires the E1-like ATG7 to bind to the
carboxyterminal glycine residue of ATG12.This binding activates ATG12 and allows the
subsequent binding with ATG10 through a thioester bond. Finally, the ATG12-ATG5
complex binds to ATG16L, forming the ATG12-ATG5-ATG16L complex which is
12

required for the recruitment of microtubule-associated protein light chain 3-II (LC3II)
[20]. The ATG12-ATG5-ATG16L complex associates with the phagophore and it is
thought to assist with the curvature of the expanding phagophore.

Once the

autophagosome is formed, this complex dissociates from the membrane [20, 27].

LC3-PE Complex
The second complex is the LC3-phosphatidylethanolamine (PE) complex. LC3 is
expressed as a cytosolic protein, upon autophagy induction; it is cleaved to LC3I by the
action of ATG4. LC3I is activated by ATG7 in a similar way that the ATG12 and then
transferred to ATG3 where it is phospholipidated, resulting in LC3II [20, 26]. LC3II is
then translocated from the cytoplasm into the autophagosome membrane to assist in
the elongation process. Simultaneously, p62 targets and binds to damaged proteins
and organelles to be engulfed by the autophagolysosome [20].
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B
ATG5-ATG12 Complex

LC3-PE Complex

E1-Like Enzyme
ATG12

ATG7

LC3
ATG12

ATG7
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ATG7

ATG4

ATG10

ATG7

ATG12
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ATG12
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ATG5
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ATG12
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Figure 4. Conjugation of the ATG5-ATG12 and LC3-PE complexes. (A) ATG5 and
ATG12 interact with each other as a result of a series of reactions mediated by ATG7
(E1-like enzyme) and ATG10 (E2-Like enzyme). The ATG5-ATG12 forms a complex
with ATG16, forming a multimeric ATG5-ATG112-ATG16 complex that binds to the
membrane of the phagophore, allowing its expansion and formation of the
autophagosome. (B) The LC3 pathway involves the cleavage of LC3 by ATG4,
resulting in LC3 which is then phospholipidated and converted into LC3II.

14

Maturation and fusion of the autophagosome with the lysosome
At this stage, the outer membrane of the lysosome fuses with the
autophagosome, forming the autophagolysosome. Proteolytic enzymes proceed to
degrade the content and the final product is recycled and reused to generate amino
acids or to produce adenosine triphosphate (ATP) for use in cell survival [20].
Importantly, since LC3 binds to the membrane of the autophagosome, it is
considered as a marker of the autophagosome and reflects induction of autophagy.
Additionally degradation of p62 and formation of double membrane autophagic
vacuoles are considered as the most common molecular and morphological markers of
autophagy.
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Cytoplasmic
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Degradation of
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Figure 5. Process of autophagy. Autophagy begins with the formation of the
phagophore membrane (nucleation), the phagophore membrane expands and
sequesters cytoplasmic material becoming a double membrane called the
autophagosome (elongation). The autophagosome membrane fuses with the
lysosomes, forming the autophagolysosome where the sequestered material is
delivered for degradation by hydrolases. Finally, this material is broken down into the
basic components of proteins and recycled as a source of energy.
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Regulation of autophagy

Induction of autophagy by mTOR
Several signaling pathways have been identified which regulate the process of
autophagy. However, the most common negative regulator of autophagy is the mTOR
pathway [27]. mTOR is a serine/threonine kinase involved in the regulation of different
cellular functions such as; survival, protein synthesis, metabolism and autophagy [28].
mTOR forms two complexes: mTORC1 and mTORC2. Under normal conditions, when
nutrients are available, mTORC1 serves as a sensor of nutrient signaling, and it is
responsible for autophagy inhibition. mTORC1 inhibits the formation of the
autophagosome by phosphorylation of ULK1 and ATG13 [29]. Under stressful
conditions such as nutrient deprivation, mTOR is inhibited and autophagy is activated,
providing the cells energy to sustain cell survival [26].
Induction of autophagy by kinases
AMPK
Additional signaling pathways can regulate autophagy. Adenine monophosphate
–activated protein kinase (AMPK) which is a cellular energy sensor; has been
described as an essential regulator of the process of autophagy through different
mechanisms [30]. It has been demonstrated that activation of AMPK in response to
stress or low ATP, inhibits mTOR activity through phosphorylation of TSC2 (tuberous
sclerosis complex-2) [2, 26, 30, 31]. It was recently discovered that, similar to
mTORC1, AMPK can regulate autophagy through direct phosphorylation of ULK1.
Egan et al. based on systemic mutagenesis analysis and in vitro phosphorylation came
to the conclusion that there are two main phosphorylation sites in ULK1:Ser317 and
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Ser777 [30-32]. Another potential target of AMPK is the transcription factor FoxO3a.
Chiacchiera et al., demonstrated that activation of AMPK resulted in accumulation of
FoxO3a and autophagy genes including ATG5, Beclin and ATG7 [33].
JNK
Activation of C-JUN N-terminal kinase (JNK) also leads to autophagy activation. One of
the mechanisms by which JNK contributes to autophagy induction is through
phosphorylation of the anti-apoptotic molecule BCL2 [26]. Phosphorylation of BCL2
prevents its binding to Beclin, allowing Beclin to form a complex with PI3K and induce
autophagy. This has been demonstrated by the work of Klein et al., who identified JNK
as essential regulator of oncolytic adenovirus-induced autophagy through the
phosphorylation of BCL2 in glioblastoma multiforme [34]. Besides regulating BCL2,
JNK can also regulates Beclin through phosphorylation of c-Jun. JNK can regulate the
expression of autophagy genes (p62, ATG5 and ATG7) [26].
ERK
Extracellular signaling-regulated kinase (ERK) is an important serine/threonine
kinase that regulates different cellular processes such as migration, proliferation and
apoptosis [26]. Sivaprasad and colleagues demonstrated that TNKFα-induced
autophagy in MCF-7 breast cancer cells is through activation of ERK [35]. In
accordance with this, Ellington et al., reported that ERK induces autophagy in human
colon cancer cells in response to soyasaponins [36]. Recent studies have shown that
ERK is also involved in the formation and maturation of autophagic vacuoles [26].
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Autophagy in Cancer
Autophagy functions to protect cells against various pathological and
physiological diseases. For example in neurodegeneration; autophagy regulates the
clearance of aggregate-prone proteins that cause neurodegenerative diseases such as
Parkinson’s disease [2]. Autophagy dysfunction or deregulation is linked to various
diseases including cancer [31].The importance of autophagy in cancer has received
increased interest within the scientific community in recent years, suggested by the
numerous ongoing clinical trials in melanoma, myeloma , renal cell carcinoma and
other cancer types,

which involve manipulation of autophagy as potential cancer

treatment [37-41]. The role of autophagy in cancer has been described as a complex
process exhibiting both cell death and cell survival functions [42]. Currently, there is
evidence to suggest the role of autophagy as a tumor suppressor in early stages of the
disease and as a cell survival mechanism in advanced stage of cancers. It can exert
this dual role in different ways and in a context-dependent manner, determined by
stage of the disease, type of cell, tissue of origin and type of stress [29, 42-44]. The
mechanisms underlying the regulation of this dual role are still unknown.

Autophagy as a cell survival mechanism
In normal cells, basal levels of autophagy are involved in cell homeostasis,
protein quality control, survival and proliferation [45]. The pro-survival role of autophagy
has been supported by studies demonstrating that organisms with loss of function of
genes that are essential for the process of autophagy have been shown to die rapidly.
Specifically, mice lacking Beclin die during embryonic development, while mice lacking
ATG5 die during neonatal period [46-48].
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In cancer cells, autophagy is upregulated under stressful conditions such as
hypoxia, nutrient deprivation as well as chemotherapy. This up-regulation confers
stress tolerance, which leads to cell survival and decreased cell death. The need for
autophagy in cancer cells is supported in different studies. Qadir et al, showed that
inhibition of different autophagy genes such as Beclin, ATG5 and ATG7, in tamoxifen –
resistant MCF-7 breast cancer cells resulted in increased cell death, suggesting
autophagy as a pro-survival mechanism [49]. Similarly, in pancreatic cancer cells,
genetic and pharmacologic inhibition of autophagy was shown to inhibit cell growth and
induce tumor regression in vivo. These results suggest that pancreatic cancer cells
require autophagy to grow [50]. Additionally, recent studies show that inhibition of
autophagy in cancer cell lines with activated Ras mutation resulted in suppression of
cell growth. These results suggest that Ras-driven cancers require autophagy for tumor
cell survival [50].These examples validate the idea that cancer cells utilize autophagy
as a mechanism that sustains cell survival under stressful conditions such as
chemotherapy.
Autophagy as a cell death-promoting mechanism
Chemotherapy is the standard and most effective cancer treatment. This type of
treatment works by inducing cell death [25, 51]. Apoptosis (Type 1 cell death) and
necrosis were the first two types of drug-induced cell death mechanisms to be
discovered. Autophagy is now considered as type II programmed cell death (PCD) or
autophagic cell death based on features and morphologic characteristics observed in
dying cells [48]. High levels of autophagy or defective apoptosis leads to cell death due
to the consumption and degradation of cellular proteins and organelles that exceed the
capacity of the cell [2, 50]. Shen and Codogno have defined autophagic cell death as 1)
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an apoptotic independent process ; 2) with increased levels of autophagic flux; and 3)
suppression of autophagy by either genetic of pharmacologic approaches inhibits cell
death [52].
In cancer cells, drug-induced autophagic cell death is cell and context
dependent. In breast cancer, silencing ATG5 in MCF-7 cells with no Bcl2 (antiapoptotic protein) inhibited doxorobucin induced autophagic cell death [53]. In lung
cancer, Kim et al., have shown that H460 cells are more sensitive to radiation treatment
when Z-DEVD, a caspase inhibitor and RAD001, an mTOR inhibitor were combined
[54]. These data indicate that in addition to the survival role of autophagy there is also a
cytotoxic function.
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Autophagy in OS
The presence of autophagy in OS has been confirmed by various studies.
However, the functional role of autophagy in OS is controversial. Shen and colleagues
have demonstrated that cisplatin, one of the agents included in the standard treatment
of OS, induces autophagy in SaOS-2 cells and promotes cell survival [55]. Inhibition of
autophagy by chloroquine, resulted in cell death.
Conversely, Wang et al., reported that Riccardin D induces cell death through
the activation of both apoptosis and autophagy mechanisms in different OS cells [56].
In addition, it has been reported that the plant alkaloid vocammine (VOA) induced
autophagic cell death in doxorobucin-resistant U2OS human OS cells [57].
In OS, the Beclin-associated autophagy related key regulator (Barkor) has been
shown to play an important role in autophagy induction. Knockdown of Barkor in U2OS
cells resulted in decreased autophagy as evidenced by decreased autophagosome
formation. In addition, the retinoblastoma (Rb) gene has been shown to repress E2
transcription factor 1 (E2F1), allowing the activation of the Beclin/Vps34 complex,
resulting in autophagy induction [58].
Huang et. al., have demonstrated that the nuclear protein, high mobility group
box 1 (HMGB1), induces autophagy by regulating the interaction of Beclin with the
ULK1-ATG12-FIP200 complex. In accordance with this, knockdown of HMGB1 in three
human OS cell lines (MG63, SaOS and U2OS) showed a significant increase in drug
sensitivity [59, 60].
Overall, there is enough evidence to demonstrate autophagy induction in OS
through different mechanisms. However, the role of autophagy in cancer, including in
OS, is complex. It can either increase cell survival or induce cell death. Modulation of
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autophagy by either increasing autophagic cell death or decreasing autophagic cell
survival may be an alternative to improve the efficacy of chemotherapy.

Modulation of autophagy
Since the process of autophagy is essential for normal cell function and
deregulation of autophagy has been associated with various pathological and
physiological diseases, modulation of autophagy has recently received a great deal of
attention by the scientific community and is an area of intensive study. This has
resulted in the discovery of a variety of autophagy modulators.
Autophagy inhibitors
There are several different pharmacologic inhibitors that have been identified
and are classified as early or late stage autophagy inhibitors. Some of the early stage
inhibitors are 3-MA and wortmannin which interfere with Vps34. Late stage inhibitors
include bafilomycin which inhibits vacuolar ATPase [50]. However, chloroquine (CQ)
and its analogue hydroxychloroquine (HCQ), have been evaluated in humans, with
HCQ the most commonly used. These two drugs prevent the acidification of the
lysosomes which in turn blocks its fusion with the autophagosome, preventing the
degradation of the cargo. The use of HCQ in a preclinical setting has demonstrated to
augment the efficacy of various chemotherapeutic agents[ [50]. However, one of the
major concerns is that in order to block autophagy, high concentrations (micromolars)
of HCQ are required. Therefore, Amaravadi and colleagues have developed Lys05, a
more potent lysosomal autophagy inhibitor. Compared to HCQ, Lys05 has been shown
to have a more potent anti-tumorigenic effect both in vitro and in vivo as a single agent
[61].
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In addition to pharmacological inhibition of autophagy, numerous studies have
used genetic inhibition as another approach to ablate autophagy. Knockdown of ATGs
such as ATG5 has been shown to effectively inhibit autophagy and exert an effect in
cell death and tumor regression in various types of cancer. Amaravadi et al.
demonstrated that shATG5 enhanced the sensitivity of lymphoma cells to
cyclophosphamide in a similar way to CQ [50, 62].

Autophagy Inducers
On the other hand, excessive autophagy can lead to cell death. Thus, autophagy
inducers have also been considered as potential anti-cancer treatment. It is well
established that inhibition of mTOR induces autophagy. Therefore, mTOR inhibitors
have been proposed as potential anti-cancer drugs. The most widely used autophagy
inducers are Rapamycin and its analogues temsirolimus (CC-779), everolimus (RAD001) and deforolimus (A3-23573), although these autophagy inducers have had limited
efficacy in clinical trials [50]. The antidiabetic drug, metformin, has also been shown to
enhance autophagy through the suppression of mTOR activity [50]. Shi et al., have
shown that metformin increases the sensitivity of lymphoma cells and inhibits their
growth via activation of AMPK which leads to the inhibition of mTOR and activation of
autophagy [63].
Even though the use of these autophagy modulators have shown to exert an
effect on enhancing the efficacy of chemotherapeutic agents, there is still a need for
more research to define the complex functions of the autophagy process in cancer. As
discussed above, autophagy can either induce cell death or cell survival. Thus. It is
necessary to define the role of autophagy in order to introduce the manipulation of
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autophagy as a potential strategy for cancer treatment. Currently, there are several
ongoing clinical trials evaluating the effectiveness of these modulators. To date, there
are no studies with a particular focus in OS.
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Aim of the study

OS is the most common type of bone cancer, causing morbidity and mortality in
children and adolescents. With the standard treatment regimens, the survival rate of
patients with localized disease is approximately 70%. However, in patients with OS
lung metastasis, the clinical outcome remains poor. A better understanding of key
molecular pathways responsible for metastatic OS cells resistance to chemotherapy
will lead to the development of novel therapeutic approaches.
Accumulating evidence suggests autophagy as a pro-survival and resistance
mechanism against cancer therapeutics in different types of cancers. Therefore, this
makes autophagy a valuable target in cancer cells. To date, little is known about the
process of autophagy in OS. We undertook this project to evaluate autophagy as a
process that protects OS cells from the cytotoxic effects of GCB allowing them to
survive and circumvent drug induced-apoptosis. The first goal of our research was to
confirm the induction of autophagy after GCB treatment in a panel of different OS cells.
After establishing whether GCB induces autophagy in OS cell lines, we set to
investigate the molecular mechanism underlying the induction of autophagy in GCBtreated OS cells. Further, we wished to determine the role of autophagy in the
sensitivity of OS cells to GCB. Understanding the process of autophagy and the
molecular pathways that regulates autophagy will allow identification of a mode to
modulate these pathways in order to enhance the activity of chemotherapy. Our
central hypothesis is that GCB-induced autophagy leads to OS cell survival and
decreased sensitivity to GCB.
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Chapter 2: Materials and Methods
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Osteosarcoma cell lines and reagents
Human LM7 metastatic OS cell line was created in our laboratory by intravenous
recycling of the parental cell line SAOS-2 through the lungs of nude mice. CCH-OS-D
cells were kindly provided by Dr. Dennis Hughes (Pediatrics Research Department,
The University of Texas MD Anderson Cancer Center). This cell line was derived from
an 18-year-old male patient with lung metastases. The K7M3 cell line was derived from
the K7M2 cell line by harvesting the lung metastasis of BALB/C mice that had been
previously injected intravenously [64]. DLM8 is a highly metastatic cell line that was
established by Asai and colleagues from LM8 and Dunn cell lines [65]. The established
OS cell line MG63 was obtained from ATCC. All cell lines were tested for mycoplasma.
A summary of each cell line is shown in Table 4. The list of reagents used in this
project is presented in Table 2, while the list of antibodies is shown in Table 3.
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Table 2. List of Reagents
Reagent

Company

2-mercaptoethanol

Fisher Scientific

Acridine Orange

Sigma-Aldrich

Alexa 488

Life Technologies

Ammonium persulfate

BioRad

Annexin V-FITC Apoptosis
detection kit
BCA Protein Assay

Calbiochem
Thermo Scientific

Bromophenol blue

Sigma

DMEM

Hyclone GE

Ethanol

Decon Laboratories, Inc

Fetal Bovine Serum

Gibco

Gemcitabine

Eli Lilly

Glycine

GenDepot

Hematoxylin

Sigma-Aldrich

Hydroxychloroquine

Sigma-Aldrich

L-glutamine

Lonza

Methanol
Nitrocellulose membranes

Fisher Scientific
BioRad

PBS

Hyclone GE

RIPA Lysis Buffer

Santa Cruz Biotechnology

SDS-PAGE standards

BioRad

Sodium dodecyl sulfate

Sigma-Aldrich

Trypan blue

Beckman Coulter

Trypsin-EDTA

Gibco

Trizma base
Visualizer Western Blot (ECL)

Sigma- Aldrich
GE Healthcare Life Sciences

Xylene

Sigma-Aldrich
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Table 3. List of antibodies
Antibody

Host

Company

Catalog
Number

LC3

Rabbit

Novus Biological

NB600-1384

ATG5

Rabbit

Novus Biological

NB110-53818

p-HSP27 Ser78/82

Rabbit

R&D Systems

AF23141

Total HSP27

Mouse

Santa Cruz

sc-13132

Beclin

Rabbit

Santa Cruz

sc-11427

SQSTM1/p62

Rabbit

Cell Signaling

5114

AKT

Rabbit

Cell Signaling

4685

phospho-AKT

Rabbit

Cell Signaling

9271

mTOR

Rabbit

Cell Signaling

2983

Phospho-mTOR

Rabbit

Cell Signaling

2971

Phospho-p70S6k

Rabbit

Cell Signaling

9205

Cleaved-caspase3

Rabbit

Cell Signaling

9661
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Cell culture
Each cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% Fetal Bovine serum (FBS), L-glutamine, sodium pyruvate, nonessential amino acids and minimal essential medium vitamin solution. Cells were
maintained in a humidified incubator with 5% CO2 at 37ºC. Each cell line was tested for
mycoplasma contamination.

Table 4. Panel of Osteosarcoma cells

Cell Line

Type of Cell

K7M3

Mouse- Metastatic

DLM8

Mouse- Metastatic

LM7

Human - Metastatic

CCH-OS-D

Human Metastatic

MG63

Human- Metastatic

Gemcitabine preparation
Gemcitabine (Gemzar) was dissolved in phosphate buffer saline (PBS) to obtain
a stock concentration of 38 mg/mL. It was then added to the cells to reach a final
concentration of 0.5, 1, 5 or 10 µM and incubated for the desired period of time.
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Autophagy modulation
Cells were treated after confluency with 15 or 20 µM of HCQ. For the dual
treatment with GCB, cells were first pre-treated with 20 µM of HCQ for 30 minutes prior
to GCB treatment.
Cell viability assay

Cells were seeded in 12-well plates and allowed to attach at 37⁰C / 5% CO2

overnight. Cells were then treated with 1 µM of GCB or GCB coupled with 20 µM of
HCQ, cells with no treatment served as control. Cells were trypsinized and viability was
analyzed by trypan blue using a cell counter (Vi-cell, Beckman Coulter). Trypan blue
exclusion assay is based on the principle that in live cells, which have an intact
membrane, the dye is not absorbed. However, in dead cells the dye can be absorbed
through the damaged cell membrane. All experiments were performed three times.
The incubation time and concentration are specified in each figure.
Western blot analysis
After the corresponding treatment, whole cell lysates were prepared by lysing
the cells with RIPA lysis buffer for 30 minutes and centrifuged at 10,000 g for 10
minutes at 4ºC. Supernatants were collected and protein concentration was determined
using Bio-Rad DC protein assay kit (500-0113-0115). Protein samples in SDS loading
buffer were boiled to 100° F during 5 minutes. Equal amounts of protein were subjected
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to

SDS-poly

acrylamide

gels

(SDS-PAGE).

Samples

were

separated

via

electrophoresis at a constant voltage of 90 V for approximately 2 ½ hr. Protein samples
were then transferred onto nitrocellulose membranes (85V for 1 hr). Membranes were
blocked in 5% milk or BSA during 1hr at room temperature and then incubated
overnight at 4⁰C with primary antibody (1:1000) against p-AKT, Akt, Beclin, cleaved
caspase-3, LC3, mTOR, p-mTOR, p-70S6K, p62, HSP27 or p-HSP27. After overnight
incubation with the corresponding primary antibody, membranes were washed with
TBS-T and incubated for one hour with secondary antibody (rabbit or mouse) at room
temperature. Signal was detected using ECL reagents (GE Healthcare Life Science).
Actin was used as loading control.
Western Blot Densitometry
Western blots were analyzed using NIH Image J software. The intensity of each
band was obtained as percentages and copied to Excel; the data was then compared
to the corresponding band intensity values of actin.
Acridine Orange (AO) Staining
Acidic Vesicular Organelles (AVO) were visualized using Acridine Orange (AO).
Following treatment with GCB, cell culture media was removed and cells were stained
with 1mg/ml AO and incubated during 15 minutes at 37ºC. After incubation, cells were
washed twice with PBS and examined under a fluorescent microscope. The autophagic
lysosomes appeared as orange vesicles in the cytoplasm of the cells, while nuclei were
stained green.

For quantification, cells were analyzed on a FACS Calibur flow

cytometer using Cell-Quest software (Becton Dickinson).
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Annexin V and PI staining
Annexin/PI staining was used to determine the percentage of apoptotic cells.
After treatment with GCB and/or HCQ, LM7 cells were washed with PBS and
trypsinized. Cells were then resuspended in binding buffer and incubated for 15
minutes with fluorescence isotiocianate (FITC) conjugated annexin V and propidium
iodide (PI). After incubation, Annexin-binding buffer was added to the samples. Cells
were analyzed using a FACS Calibur flow cytometer using Cell-Quest software
(Becton-Dickinson).

Electron Microscopy
Cells were seeded in 6-well plates and treated with GCB. After treatment,
samples were fixed with a solution containing 3% glutaraldehyde plus 2%
paraformaldehyde in 0.1 M cacodylate buffer at pH 7.3 and stored at 4°C. After
fixation, samples were submitted to the MD Anderson electron microscopy core facility.
At the core facility, Mr. Kenneth Dunner Jr, processed the samples. Briefly, samples
were washed in 0.1 M cacodylate buffer and treated with 0.1% Millipore-filtered
buffered tannic acid, postfixed with 1% buffered osmium tetroxide for 30 minutes, and
stained with 1% Millipore-filtered uranyl acetate. The samples were washed several
times in water, then dehydrated in increasing concentrations of ethanol, infiltrated, and
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embedded in LX-112 medium. The samples were polymerized in a 60⁰C oven for 2

days. Ultrathin sections were cut in a Leica Ultracut microtome (Leica), stained with
uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010
transmission electron microscope (JEOL, USA, Inc.) at an accelerating voltage of 80
kV.

Digital images were obtained using AMT Imaging System (Advanced

Microscopy Techniques Corp).
Human Phospho-kinase Antibody Array
The human phospho-kinase Antibody Array kit was purchased from R&D
systems. CCH-OS-D and LM7 cells were treated with GCB for 48 and 72 hrs
respectively. Untreated cells were used as a control. The cells were collected and lysed
using Lysis Buffer 6 provided by the manufacturer. Protein concentration was
determined by Bradford Protein Assay (Bio-Rad). Nitrocellulose membranes containing
different phospho-specific antibodies to each kinase in duplicate were blocked during
one hour and then incubated with 400 µg of protein at 4⁰C. After overnight incubation,
the membranes were washed and incubated with Detection Antibody Cocktails of
biotinylated antibodies. Finally, protein was detected by using HRP-conjugated
streptavidin antibodies and chemiluminescent detection reagents.
RNA interference
Lentiviral Beclin and ATG5 shRNA (Open Biosystem) was used to knockdown
BECN and ATG5 protein expression. Control cells were infected with lentivirus
35

containing empty shRNA vector. Briefly, 293T cells were transfected with the 7ug/ml of
the plasmid, 5 ug/ml psPAX2 and 4 ug/ml pMD2. After 48 hrs, 2 ml of supernatant
containing lentivirus was collected and used for infection by adding it to each well of a
6-well plate containing 1x105 cells. Cells were incubated for 12 hrs and transferred to a
75 mm flask. Confirmation of Beclin and ATG5 protein knockdown was determined by
western blot analysis.

Mice studies
Animal studies were performed in accordance with the institutional guidelines,
approved by the MD Anderson Institutional Animal Care and Use Committee (IACUC).
Female nude mice were purchased from the National Cancer Institute (NCI).
Tumor implantation and GCB treatment
Nude mice were injected with 3 x 106 LM7 cells via the tail vein. Formation of
lung metastases was verified after five weeks by hematoxylin and eosin (H&E) staining.
Mice were randomly divided in 2 groups and received 0.5 mg/kg twice weekly of
aerosol GCB or PBS (as control) for six weeks.
BALB/C mice were inoculated with 0.5 x 10

6

K7M3 cells via the tail vein. Formation of

lung metastases was verified after one week by H&E staining. Mice were also randomly
divided in 2 groups and received 0.5 mg/kg twice weekly of aerosol GCB or PBS (as
control) for four weeks.
Immunohistochemistry
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Paraffin samples (lung tissue sections) were warmed for 15 minutes at 60°C and
de-paraffinized in xylene, rehydrated in serial dilutions using ethanol and antigen
retrieval. Sections were then incubated with 3% hydrogen peroxide followed by 4% fish
gelatin. The primary antibody, polyclonal rabbit anti-LC3B, was applied to the sections
and left overnight at 4˚C. The secondary antibody labeled with horseradish peroxidase
was then applied at room temperature for 1 hour. The slides were then developed with
3, 3’-diaminobenzidine and counterstained with hematoxylin.

Immunocytochemistry
K7M3, CCH-OS-D and LM7 cells were grown on glass coverslips. After
treatment with GCB, the media was removed; cells were washed with PBS and fixed
with 4% paraformaldehyde at room temperature for 15 minutes. After fixation, cells
were washed with PBS and permeabilized with Triton X in PBS containing BSA for 30
minutes. Cells were washed again with PBS and incubated with anti-LC3 specific
antibody, overnight. Cells were incubated with the secondary anti- rabbit and Alexa
Fluor 488 for one hour at room temperature. Finally the cells were washed with PBS
and immediately observed using a Leica DM5500B Microscope.

Statistical analysis
Data were expressed as an average of three independent experiments.
Experimental data were analyzed using GraphPad PRISM Software. P-values <0.05
were considered significant.
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Chapter 3: Sensitivity of osteosarcoma cells to Gemcitabine
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Rationale and Aims
Previous work from our laboratory has demonstrated the significant therapeutic
effect of GCB against OS cells [18, 19]. However, after GCB treatment a subset of cells
persist as small isolated lung metastases in vivo.

Initial studies were designed to

assess the sensitivity of a panel of OS cells to GCB treatment. An in vitro dose
response study was performed using various concentrations of GCB during different
time points, and the effects on cell viability were analyzed. These dose response
experiments were conducted on three OS cell lines: K7M3, CCH-OS-D and LM7 cells,
with the purpose of evaluating the response of these metabolically different cells and to
compare their sensitivity to GCB treatment.
To further our knowledge about the sensitivity of OS cells to GCB we designed
experiments to assess whether apoptosis was induced following GCB treatment. OS
cells were treated with GCB and western blot analysis was performed for caspase-3
cleavage (activation), which is an essential marker of the apoptotic process.
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Results
Gemcitabine cytotoxic effect varies within OS cell lines
To investigate the sensitivity of OS cells to GCB; K7M3, LM7 and CCH-OS-D
OS cells were treated with increasing concentrations of GCB (0.5 to 10 µM) for up to 72
hrs. GCB cytotoxic effects and induction of apoptosis were determined by trypan blue
exclusion assay and western blot for cleaved caspase 3, respectively.
As shown in figure 6, a significant decrease in k7M3 cell viability was observed
as soon as 24 hrs. When compared to the control, the viability of K7M3 cells did not
show a significant decrease when treated with 0.5 µM. However, when treated with 1
µM, the viability decreased to 47% (p<0.05). Doses of 5 and 10 µM did not induce any
additional decrease in viability (5 µM: 51%; 10 µM: 48% p<0.05). At 48 hrs a significant
decrease in viability (44.33% p<0.05) was observed with 0.5 µM of GCB. Cells treated
with 1, 5 and 10 µM further decreased cell viability (1 µM: 28.3%; 5 µM: 23.4%; 10 µM:
30.0% p<0.05). At 72 hrs the viability was 45.8% (p<0.05) when cells were treated with
0.5 µM of GCB. Higher doses further decreased cell viability (1 µM: 34.8%; 5 µM: 23%;
10 µM: 22.5% p<0.05).
Next, we wanted to determine whether the cytotoxic effect of GCB is due in part
to apoptosis. As shown by western blot analysis, increase cleaved caspase 3 protein
levels were observed when K7M3 cells were treated with different doses of GCB and
compared to control cells.
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Figure 6. GCB decreased the viability of K7M3 OS cells and induced caspase 3
activation. Trypan blue exclusion assay was performed in order to assess the effect of
different doses of GCB on cell viability over 24, 48 or 72 hrs period. (B) Analysis of
GCB-induced OS cell death. Western blot analysis was performed using specific
antibody for caspase 3. Actin was used as a loading control.
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In response to increasing concentration of GCB, the viability of LM7 cells was
significantly decreased over a period of 24 hrs when treated with 5 and 10 µM (5 µM:
56.0%; 10 µM: 53.8% p<0.05). No significant decrease in cell viability was observed
when treated with 0.5 or 1 µM. After 48 hrs, cell viability significantly decreased for all
GCB doses (0.5 µM: 68%; 1 µM: 70.5%; 5 µM: 67.2%; 10 µM: 56.05% p<0.05). After
72 hrs, cell viability was significantly reduced for all treatment doses (0.5 µM: 58.65%;
1 µM: 56.57%; 5 µM: 54.27%; 10 µM: 39.25% p<0.05).
Analysis of expression of cleaved caspase 3 by western blot, revealed that
compared to untreated group, GCB induced cleaved caspase 3 starting at 24 hrs with a
marked

increased

at

48

hrs,

followed

by

a

decreased

at

72

hrs.
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Figure 7. GCB decreased the viability of LM7 OS cells and induced caspase 3
activation. Trypan blue exclusion assay was performed in order to assess the effect of
different doses of GCB on cell viability over 24, 48 or 72 hrs period. (B) Analysis of
GCB-induced OS cell death. Western blot analysis was performed using specific
antibody for caspase 3. Actin was used as a loading control.
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After 24 hrs of GCB treatment the viability of CCH-OS-D cells was significantly
reduced for the 5 and 10 µM doses (5 µM: 73.97%; 10 µM: 49.45% p<0.05). No
significant reduction in viability was observed for the lower doses of 0.5 and 1µM
(0.5µM: 73.23%; 1µM:72.73%). At 48 hrs, significant decrease in cell viability was
observed for all treatment doses (0.5 µM: 56.33%; 1.0 µM: 50.5%; 5 µM: 52.67%; 10
µM: 45.1% p<0.05). Similar results were observed after 72 hrs of GCB treatment (0.5
µM: 26.73%; 1.0 µM: 26.03%; 5 µM: 22.67%; 10 µM: 19.53% p<0.05). In CCH-OS-D,
expression of cleaved caspase 3 was also increased followed GCB treatment.
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Figure 8. GCB decreased the viability of CCH-OS-D OS cells and induced
caspase 3 activation. Trypan blue exclusion assay was performed in order to assess
the effect of different doses of GCB on cell viability over 24, 48 or 72 hrs period. (B)
Analysis of GCB-induced OS cell death. Western blot analysis was performed using
specific antibody for caspase 3. Actin was used as a loading control.
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Next, we compared the response of the three OS cell lines to GCB treatment
after 72 hrs treatment. In Figure 9, comparison between the three cell line’s viability
when treated with 1 µM of GCB shows significant reduction in all three cell lines. We
noticed that the viability of LM7 cells was significantly higher (57%) compared to the
viability of K7M3 (26%) and CCH-OS-D (34%) cells. These results suggest, that LM7
cells were less sensitive to GCB treatment compared to the other two cell lines.

Figure 9. Viability of K7M3, CCH-OS-D and LM7 OS cells after 72 hrs treatment
with GCB. Trypan blue exclusion assay was performed in order to assess the effect of
of GCB (1µM) on cell viability over 72 hrs period.
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Summary
Although we have previously shown that GCB has a significant therapeutic effect
against OS cells, resistance remains a challenge for the treatment of OS. The aim of
this chapter was first to perform an analysis of sensitivity on three different OS cell lines
(K7M3, CCH-OS-D and LM7) and secondly assess whether apoptosis was induced.
For this purpose we performed a dose response analysis to evaluate the
response of each OS cells to GCB treatment. The results obtained in the K7M3 cells
showed that a significant decrease in cell viability was obtained with 0.5 µM of GCB as
soon as 24 hrs. When analysis was performed in the CCH-OS-D cells, initial tolerance
to 0.5 µM of GCB was observed. Significant decrease in cell viability was detected
following treatment with 5 and 10 µM. These results suggest that CCH-OS-D cells were
able to tolerate higher concentrations of GCB than K7M3 cells; viability was higher than
50% at 5 and 10µM doses. Similar results were observed in LM7 cells. As shown by
the dose response graphs, a plateau was reached in cell viability indicating that higher
doses offer no benefit in decreasing cell viability.
Figure 9 represents the viability of K7M3, CCH-OS-D and LM7 cells after 72hrs.
When the viability was compared between the three cell lines, K7M3 and CCH-OS-D
cells were the most sensitive cells. LM7 cells were relatively less sensitive to treatment
when compared to the other cell lines.
The expression of cleaved caspase-3, a typical marker of apoptosis was
assessed by western blot analysis. The expression of cleaved caspase 3 was
increased in GCB treated OS cell lines compared to the control cells, suggesting
apoptotic-induced cell death.
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All together, these results indicate that treatment of OS cells with GCB
decreased cell viability and induced apoptosis. This data supports the idea that GCB
may be useful for the treatment of OS. However, evidence of cell resistance was
suggested by a population of cells that remain viable after treatment.
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Chapter 4: Gemcitabine induces autophagy in OS cells
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Rationale and Aims
Several studies have shown that autophagy is induced in cancer cells following
chemotherapeutic treatment with anti-cancer drugs and radiation [66]. It is reported that
GCB can induce autophagy in pancreatic and breast cancer cells [67, 68]. However,
GCB-induced autophagy has not been addressed in OS.
It is therefore relevant to study autophagy induction in OS after treatment with
GCB, which may reveal autophagy as a possible target to improve GCB induced OS
cell death. With the above mentioned rationale, the aim of this chapter is to determine
whether there is autophagy induction after treatment with GCB on different OS cell
lines.
In order to address this aim, we utilized different methods for studying
autophagy induction in K7M3, LM7, CCH-OS-D, DLM8 and MG63 OS cells after GCB
treatment. We utilized various cellular marker such as Acidic Vesicular Organelles
(AVO), biochemical markers (Beclin, LC3 and p62) and ultrastructure analysis of
double membrane autophagic vesicles.
In addition, we assessed the induction of autophagy after aerosol GCB
treatment in two OS mouse models by evaluating the expression of autophagic
markers in OS lung metastasis nodules and the formation of autophagic vesicules by
electron microscopy.
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Results
GCB induces formation of Acidic Vesicular organelles.
As part of the process of autophagy, the autophagosome fuses with the
lysosome forming the autophagolysosomes (acidic structures). Accordingly, Acidic
Vesicular Organelles (AVO) staining was performed to evaluate the formation of
autophagolysosomes, as well as quantification using flow cytometry. For this, we used
Acridine Orange (AO); a lysotropic dye that accumulates in acidic cellular
compartments. The incorporation of AO was visualized by fluorescence microcopy in
untreated and treated OS cells.

As shown in figure 10, AVO induced by GCB stain

orange-red, where the cytoplasm of cell stains green. Control cells show basal
autophagy levels while GCB-treated cells exhibited increased AVOs formation when
compared to the untreated cells.
Since the intensity of red fluorescence is proportional to the acidic vesicular
compartments, we used flow cytometry to quantified AVO formation. On K7M3 cells,
AVO formation increased after 24 hrs of treatment to 13.5%. At 48 hrs, AVO formation
increased to 61.3%, and at 72 hrs it increased to 35.2%, all results compared to
untreated cells. On LM7 cells, AVO formation increase to 3.3%, 8.0% and 21.96% at
24, 48 and 72 hrs respectively. CCH-OS-D cells also demonstrated increase AVO
formation with increases to 2.3%, 10.0% and 18.07% at 24, 48 and 72Hrs respectively.
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Figure 10. Induction of Acidic vesicular organelles in OS cells after GCB
treatment. Cells were treated with 1 µM of GCB during 24, 48 and 72 hrs. Acridine
orange (1 µg/mL) was added for 15 minutes. Formation of AVO was visualized using a
fluorescence microscope.
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Figure 11. Quantification of Acidic vesicular organelles in OS cells after GCB
treatment. Cells were treated with 1 µM of GCB during 24, 48 and 72 hrs. Acridine
orange (1 µg/mL) was added for 15 minutes. Quantification of AVO was performed by
flow cytometry. Untreated cells were used as a control. Graphs indicate the percentage
of AVO-positive cells.
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GCB increases Beclin expression, conversion of LC3I to LC3II and decrease of
p62.
To confirm autophagy induction after GCB treatment, changes in protein
expression of different autophagic markers: Beclin, LC3 and p62 were assessed using
Western Blot and quantified by densitometry using ImageJ software. After GCB
treatment, an increase in the expression of Beclin, an essential protein for the formation
of the isolation membrane, was observed in all OS cells when compared to control
group [69].
LC3 is a common autophagic marker. Upon induction of autophagy, LC3I is
phospholipidated and converted to LC3II. Therefore the conversion of LC3I to LC3II is
a reliable marker of autophagy and an indicative of autophagic activity [55, 69]. As
shown in Figures 12-14, there was an increase in the conversion of LC3I/LC3II in GCBtreated OS cells as compared to untreated control.
The adaptor protein p62 is a marker of autophagic flux and is required for the
formation of protein aggregates [55]. It is incorporated into the autophagosomes and
degraded. Therefore, the expression of p62 inversely correlates with the autophagic
activity. As an alternate approach to evaluate autophagic flux, we also assessed the
expression of p62 in GCB-treated OS cells. As expected, there was a marked reduction
in p62 protein expression in K7M3, CCH-OS-D and LM7 OS cells, further indicating
that GCB-induced autophagy in OS cells (Figures 12-14).
Western blots from DLM8 and MG63 cells shows a similar pattern: increased
Beclin expression and increased conversion of LC3I to LC3II in figures 15 and 16.
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Figure 12. GCB induces autophagy in K7M3 OS cells. OS cells were grown in
corresponding media until confluence, treated with GCB during 24, 48 and 72 hrs. Then
cells were collected and lysed with RIPA buffer. Equal amount of total protein was
resolved in SDS-PAGE, transfer to a nitrocellulose membrane and blotted using
antibodies specific for each protein, using actin as a loading control. Western blot
analysis and densitometry illustrate changes in Beclin, LC3 and p62 protein expression
in response to GCB treatment.
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Figure 13. GCB induces autophagy in LM7 OS cells. OS cells were grown in
corresponding media until confluence, treated with GCB during 24, 48 and 72 hrs. Then
cells were collected and lysed with RIPA buffer. Equal amount of total protein was
resolved in SDS-PAGE, transfer to a nitrocellulose membrane and blotted using
antibodies specific for each protein, using actin as a loading control. Western blot
analysis and densitometry illustrate changes in Beclin, LC3 and p62 protein expression
in response to GCB treatment.
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Figure 14. GCB induces autophagy in CCH-OS-D OS cells. OS cells were grown in
corresponding media until confluence, treated with GCB during 24, 48 and 72 hrs. Then
cells were collected and lysed with RIPA buffer. Equal amount of total protein was
resolved in SDS-PAGE, transfer to a nitrocellulose membrane and blotted using
antibodies specific for each protein, using actin as a loading control. Western blot
analysis and densitometry illustrate changes in Beclin, LC3 and p62 protein expression
in response to GCB treatment.
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Figure 15. GCB induces autophagy in DLM8 OS cells. OS cells were grown in
corresponding media until confluence, treated with GCB during 24, 48 and 72 hrs. Then
cells were collected and lysed with RIPA buffer. Equal amount of total protein was
resolved in SDS-PAGE, transfer to a nitrocellulose membrane and blotted using
antibodies specific for each protein, using actin as a loading control. Western blot
analysis and densitometry illustrate changes in Beclin and LC3 protein expression in
response to GCB treatment.
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Figure 16. GCB induces autophagy in MG63 OS cells. OS cells were grown in
corresponding media until confluence, treated with GCB during 24, 48 and 72 hrs. Then
cells were collected and lysed with RIPA buffer. Equal amount of total protein was
resolved in SDS-PAGE, transfer to a nitrocellulose membrane and blotted using
antibodies specific for each protein, using actin as a loading control. Western blot
analysis and densitometry illustrate changes in Beclin and LC3 protein expression in
response to GCB treatment.
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GCB Increases Immunofluorescent punctate staining of LC3 in OS cells.
Another approach for monitoring autophagy is fluorescence microscopy. In
particular, accumulation of LC3 punctate is commonly assessed, as a hallmark of
autophagy. Therefore, following exposure to GCB, cells were fixed in coverslips and
immunostained with LC3 antibody. After incubation, cells were visualized under a
fluorescence microscope. As shown in figure 17, accumulation of LC3 green
fluorescent dots was higher in K7M3, CCH-OS-D and LM7 GCB- treated cells,
compared to the control that exhibits diffuse and weak LC3 punctate dots.

Figure 17: LC3 punctate increased after GCB treatment in OS cells. Cells were
treated with GCB during 48 hrs, fixed and immunostained with LC3 antibody. Following
treatment, fluorescence was observed under a fluorescence microscope. Arrows
indicate LC3 punctate.
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Electron microscopy revealed increased formation of autophagosomes in OS
cells after GCB treatment.
In 1963, Christian de Duve described autophagy through the use of Electron
Microscopy (EM) [70]. Since then, electron microscopy is commonly used for the
detection of autophagic vacuoles.
Therefore, we used EM to confirm our previous results. We treated the K7M3,
LM7, CCH-OS-D and MG63 OS cells with GCB and examined the formation of
autophagosomes via electron microscopy. As shown in figures 18 and 19, GCBtreated OS cells exhibited a high number of double membrane autophagic vacuoles
which indicates autophagosome and/or autolysosome formation. On the contrary,
untreated cells exhibited low or no number of autophagosomes.
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Figure 18: GCB treatment increases autophagosome formation in K7M3 and LM7
cells. A) K7M3, B) LM7 cells were treated with GCB. Electron microscopy was used to
visualize the double membrane vacuoles that form during GCB-induced autophagy.
Images of whole cells (2 microns) and corresponding higher magnification (500 nm) for
each cell line were collected to detect autophagic vacuoles.
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Figure 19: GCB treatment increases autophagosome formation in CCH-OS-D and
LM7 cells. A) CCH-OS-D and B) MG63 cells were treated with GCB. Electron
microscopy was used to visualize the double membrane vacuoles that form during
GCB-induced autophagy. Images of whole cells (2 microns) and corresponding higher
magnification (500 nm) for each cell line were collected to detect autophagic vacuoles.
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Aerosol GCB induces autophagy in OS lung metastasis
Since our results indicated that GCB induces autohagy in OS cells in vitro, we
investigated the effect of aerosol GCB on autophagy induction in vivo in two different
OS mouse models. We anticipated that aerosol GCB would also induce autophagy in
OS lung metastasis in vivo. Electron microscopy of fixed tissues and detection of some
biochemical markers of autophagy such as LC3 and Beclin has been used as tools to
monitor autophagy in different mouse models.
We utilized two of our OS pulmonary metastasis models; LM7 and K7M3. Even
though these lung metastasis models are well established in our laboratory, we wanted
to confirm the ability of these cells to form metastasis before beginning treatment with
aeroosol GCB. For that reason, we injected the human LM7 cells intravenously in nude
mice and confirmed formation of pulmonary metastasis by H&E staining at 5 weeks
post-injection. The mouse K7M3 OS cells were injected intravenously into BALB/C
mice. Lungs were extracted and presence of metastasis was demonstrated by H&E at
6 days post-injection (Figure 20 and 21). After formation of metastastasis was
confirmed, nude mice were treated with PBS or 0.5 mg/kg of aerosol GCB twice a week
for a total of five weeks. Treatment in BALB/C mice was started on week two for up to
four weeks. Mice were treated with 0.5 mg/kg of aerosol GCB twice a week. Mice were
sacrificed at the end of the treatment and lungs were resected for further studies.
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A

B

Figure 20 . Schematic diagram of In vivo model experimental design. (A) Nude
mice were injected intravenously with 3x106 LM7 cells. Formation of micrometastasis
was evaluated at week 5 and confirmed by H&E staining. Treatment was started on
week six. Mice were treated with PBS or 0.5 mg/kg of aerosol GCB twice a week for a
total of five weeks. (B) BALB/C mice were injected with 0.5x106 of K7M3 cells.
Micrometastasis were confirmed after one week. Treatment was started on week two
for up to four weeks. Mice were treated with 0.5 mg/kg of aerosol GCB twice a week.
Mice were sacrificed at the end of the treatment and lungs were resected for further
studies.
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LM7

K7M3

Figure 21. LM7 and K7M3 cells form pulmonary metastasis in mouse models.
Mice were sacrified and lungs were extracted. H&E staining was perfomed to confirm
the presecence of metastasis.
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Aerosol GCB increases the expression of LC3 and Beclin in K7M3 OS lung
metastases.
Immunohistochemical staining for LC3 and Beclin was utilized to detected
autophagy

induction

in

metastatic

OS

lung

tissues

after

GCB

treatment.

Immunohistochemical analysis of metastastic tumors resected from mice of PBS
(control) and GCB treated groups demonstrated that LC3 and Beclin expression was
significantly increased in pulmonary metastatic tumors from mice of the treated group.
Similar results were obtained in LM7 OS lung metastasis from the treated group.

K7M3

Figure 22. Increased expression of LC3 and Beclin in K7M3 OS lung metastasis
after GCB treatment. At the end of the treatment BALB/C mice injected with K7M3
cells were sacrificed, and their lungs were extracted. Immunohistochemistry staining
was performed using specific antibodies for LC3 and Beclin.
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Aerosol GCB increases the expression of LC3 and Beclin in LM7 OS lung
metastases

Figure 23. Increased expression of LC3 and Beclin in LM7 OS lung metastasis. At
the end of the treatment Nude mice injected with LM7 cells were sacrificed, and their
lungs were extracted. Immunohistochemistry staining was performed using specific
antibodies for LC3 and Beclin.
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Aerosol GCB increases the formation of autophagic vacuoles in K7M3 and LM7
OS lung metastasis.
In order to validate aerosol GCB-induced autophagy in lung metastasis, we
resected the lungs and assessed the formation of autophagosomes by electron
microscopy. Treated cells exhibited increased formation of double membrane
autophagic vacuoles when compared to control cells.

500 nm

500 nm

500 nm

500 nm

Figure 24. GCB induces
formation of double membrane
autophagic vacuoles in OS lung metastasis. Following aerosol GCB treatment,
lungs were resected and examined by electron microscopy. Representative pictures of
electron microscopy in mouse OS lung metastasis are shown as whole cells (2
microns) and corresponding higher magnification (500 nm).
4.2.5 Summary
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In the previous chapter, it was observed that after GCB treatment some cells
persist as viable cells. We have previously demonstrated that few isolated lung
metastasis remained behind after GCB treatment. It was then hypothesized that a
mechanism of resistance was acquired by OS cells that decreases cell sensitivity and
GCB efficacy. Since autophagy has been described to be induced by chemotherapeutic
agents; in this chapter we aimed to determine whether GCB induces autophagy in OS
cells.

There are different methods for the monitoring and detection of autophagy,

including assessment of AVO, biochemical markers such as LC3, p62 and Beclin and
ultrastructure visualization of autophagosome formation.
From our initial results with Acridine Orange, GCB-treated cells have higher
AVO formation when compared to the untreated cells, suggesting induction of
autophagy. Although Acridine Orange is a well-known and used approach to detect
autophagic vesicles, it is not specific to autophagic vesicles. It can also be retained in
other acidic compartments such as endocytic vesicles and secretory vesicles [71].
Therefore, we decided to support these results with the use of multiple techniques of
autophagy detection.
Induction of autophagy was also evidenced by western blots analysis of different
biochemical markers responsible for autophagy induction. Beclin is part of an upstream
complex responsible for the initiation step and formation of the isolation membrane
[69]. Significant increase in Beclin protein expression was observed in all OS cell lines
after GCB treatment.
Upon induction of autophagy, LC3I is conjugated to PE and converted to LC3II.
LC3II then binds to the autophagosome membrane [71]. Therefore, LC3 is one the
most common autophagic marker.

Significant conversion of LC3I to LC3II was
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observed in all cell lines, indicating autophagy induction by GCB treatment. This
increase in LC3 was confirmed by the fluorescent microscope data, which
demonstrates accumulation of LC3 punctate after treatment (Figure 17). During late
autophagy, LC3II is degraded and recycled, therefore in some cases the lack of
increase in LC3II may be due to continued recycling. For this reason even though LC3
is one of the most common autophagy markers, it is necessary to confirm using other
markers.
Since the induction of autophagy goes along with the degradation of p62,
determining the status of p62 is commonly used to assess the autophagic flux [55]. p62
is implicated in targeting and recruiting proteins and organelles for degradation [72]. It
has also been proposed that it binds to LC3 and localizes to the autophagosome where
it becomes degraded. Therefore, during autophagy induction, total levels of p62 are
inversely correlated with autophagic activity. Following GCB treatment, protein levels of
p62 were evaluated by western blot. There was a significant decrease in p62 levels in
the treated cells, which is consistent with induction of autophagic flux.
After assessment of lysosomal formation, as well as proteins involved in
autophagy induction, we decided to validate our data by the use of electron
microscopy. To date, this is the standard and most reliable method for monitoring
autophagy. It was using electron microscopy that the phenomena of autophagy was
discovered in rat parenchymal cells [73].
Ultrastructural analysis by electron microscopy showed that GCB-treated OS
cells exhibited formation of abundant autophagic vacuoles. A higher magnification of
these vacuoles confirmed that they were in fact double membrane vacuoles. On the
contrary, untreated cells contain only few or no autophagic vacuoles.
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We concluded that GCB treatment induces autophagy in OS cells, suggested by
increase in AVO, increase in Beclin expression, conversion of LC3I to LC3II, decrease
in p62 and accumulation of double membrane autophagic vacuoles.
Based on the in vitro results, that GCB induces autophagy in OS cells, we
hypothesized that aerosol GCB would also induce autophagy in vivo. To test this
hypothesis, we used immunohistochemistry staining to evaluate induction of autophagy
following GCB treatment in two OS mouse models.
By comparing the expression of LC3 and Beclin in resected lung tissue between
mice treated with aerosol GCB and control mice, we demonstrated that mice in the
treated group exhibited an increase in the accumulation of autophagy markers
confirming that GCB can also induce autophagy in OS lung metastases.
In support of our hypothesis that aerosol GCB would also induce autophagy in
OS lung metastases in mice, we sought to determine if treatment of mice with aerosol
GCB resulted in formation of double membrane autophagic vacuoles, a feature of
autophagosomes. Following aerosol GCB treatment, mice were sacrificed and lungs
were submitted and analyzed using electron microscopy. A significant increase in the
formation of autophagic vacuoles was reported associated with the treatment,
compared to the control group. All these results confirmed autophagy induction after
treatment with GCB in OS cells both in vitro and in vivo.
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Chapter 5: AKT/mTOR signaling pathway as the molecular mechanism involved
in Gemcitabine-Induced autophagy in osteosarcoma

Rationale and Aims:
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Having demonstrated that GCB induces autophagy in OS, we investigated the
potential molecular mechanism underlying the induction of autophagy after GCB
treatment.

A variety of signaling events that regulate autophagy have been

investigated. However, the AKT/mTOR pathway is the most common regulatory signal
of autophagy. mTOR is a well-established negative regulator of autophagy [2, 27, 74].
Activation of AKT through growth factors and nutrients, serve as signal to the cells to
know that recycling of cellular components is not necessary and energy should be
spend in other cellular processes such as cell proliferation and protein synthesis
through mTOR activation [75].
Therefore, we examined whether GCB inactivates this pathway thereby inducing
autophagy. In order to answer this question, we investigated the phosphorylation status
of key components of the AKT/mTOR signaling pathway.

We expected to see a

decreasing trend in the phosphorylation of the key components of this signaling
pathway, leading to activation of autophagy.

Results
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Phosphorylation of AKT and mTOR is decreased after GCB treatment.
Our studies began by utilizing western blot analysis to determine the
phosphorylation status of AKT and mTOR. We treated the K7M3, LM7 and CCH-OS-D
OS cells with GCB and the cell lysates were analyzed by western blot with specific
antibodies for each protein and their phospho-counterparts. As shown in figure 25,
western blot analysis revealed that phosphorylation of AKT (S473) and mTOR (S2448)
was significantly decreased in K7M3, LM7 and CCH-OS-D cells by GCB as compared
to the untreated cells, suggesting the implication of this pathway in GCB-induced
autophagy. The non-phosphorylated form was not affected.
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Figure 25. GCB treatment decreases AKT and mTOR phosphorylation in OS cells.
K7M3, LM7 and CCH-OS-D OS cells were treated with 1µM of GCB for 48 or 72 hrs.
AKT and mTOR phosphorylation was examined with anti-phospho-AKT and antiphospho mTOR antibody. Total levels were examined with an anti-AKT and antimTOR antibody. Actin was used as a loading control.
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Phosphorylation of AKT, mTOR, PRAS40 and P70S6K decreased after GCB
treatment
To confirm that the AKT/mTOR pathway is involved in GCB-induced autophagy
in OS cells, we utilized a high-throughput screening antibody array to evaluate the
phosphorylation status of AKT and mTOR and determine the involvement of any other
kinase. Following GCB treatment we analyzed the cellular content by using a Human
Phospho-Kinase Antibody Array (R&D systems). The results demonstrated that a great
number of kinases exhibited changes in phosphorylation after treatment (Figure 26 and
27, Table 5). As expected, we observed a decrease in AKT (S473) and mTOR (2448)
phosphorylation after 48 hrs of GCB treatment in CCH-OS-D cells and after 72 hrs in
the LM7 cells.
As the proline-rich AKT substrate of 40kDa (PRAS40) has been reported as a
substrate of AKT, we investigate the effect of GCB on the phosphorylation status of
PRAS40 [76]. In accordance with this idea, as shown in figures 28 and 29 the
phosphorylation of PRAS40 decreased after GCB treatment in both OS cell lines.
p70S6K is a downstream target of mTOR [77]. To more deeply investigate, we also
evaluate the effect of GCB on the phosphorylation status of p70S6K. As shown in
figures 28 and 29 the phosphorylation p70S6K (T421/S424) was also decreased after
GCB treatment in both OS cell lines.
The Human Phospho-Kinase array was unable to properly detect p70S6k to
acceptable levels. In order to assess protein levels, it was decided to perform a western
blot analysis and quantification by densitometry. After 48 hrs of GCB treatment,
p70S6K expression levels had decreased.
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LM7

Figure 26. Human phospho-kinase array reveals numerous phosphorylated
kinases in LM7 OS cells after GCB treatment. Human phospho-kinase array was
utilized to evaluate the phosphorylation status of several kinases during GCB treatment
in human OS cells. LM7 cells were treated during 72 hrs and whole cell lysates were
analyzed by the array. Each spot indicates phospho-protein levels and controls in
duplicate. See Table 5 for the complete list of kinases.
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CCH-OS-D

Figure 27. Human phospho-kinase array reveals numerous phosphorylated
kinases in CCH-OS-D OS cells after GCB treatment. Human phospho-kinase array
was utilized to evaluate the phosphorylation status of several kinases during GCB
treatment in human OS cells. CCH-OS-D cells were treated during 48 hrs and whole
cell lysates were analyzed by the array. Each spot indicates phospho-protein levels and
controls in duplicate. See Table 5 for the complete list of kinases.
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Kinase\Control
Reference Spot
p38α
ERK1/2
JNK
GSK-3α/β
p53
Reference Spot
EGFR
MSK1/2
AMPKα1
AKT
AKT
p53
mTOR
CREB
HSP27
AMPKα2
β-catenin
p70S6 kinase
p53
c-jun
Src
Lyn
Lck
STAT2
STAT5a
p70S6 kinase
RSK1/2/3
Enos
Fyn
Yes
Fgr
STAT6
STAT5b
STAT3
p27
PLC-у1
Hck
Chk-2
FAK
PDGF Rβ
STAT5a/b
STAT3
WNK1
PYK2
Reference Spot
PRAS40
PBS(Negative Ctrl)
HSP60
PBS(Negative Ctrl)

Phosphorylation Site
T180/Y182
T202/Y204/T185/Y187
T183/Y185,T221/Y223
S21/S9
S392
Y1086
S376/S360
T183/Y185,T221/Y223
S473
T308
S46
S2448
S133
S78/S82
T172
T389
S15
S63
Y419
Y397
Y349
Y698
Y694
T421/S424
S380/S386/S377
S1177
Y420
Y426
Y412
Y641
Y699
Y705
T198
Y783
Y411
T68
Y397
Y751
Y694/Y699
S727
T60
Y402
T246

Membrane Coordinates
A-A1,A2
A-A3,A4
A-A5,A6
A-A7,A8
A-A9,A10
B-A13,A14
B-A17,A18
A-B3,B4
A-B5,B6
A-B7,B8
A-B9,B10
B-B11,B12
B-B13,B14
A-C1,C2
A-C3,C4
A-C5,C6
A-C7,C8
A-C9,C10
B-C11,C12
B-C13,C14
B-C15,C16
A-D1,D2
A-D3,D4
A-D5,D6
A-D7,D8
A-D9,D10
B-D11-D12
B-D13,D14
B-D15,D16
A-E1,E2
A-E3,E4
A-E5,E6
A-E7,E8
A-E9,E10
B-E11,E12
B-E13,E14
B-E15,E16
A-F1,F2
A-F3,F4
A-F5,F6
A-F7,F8
A-F9,F10
B-F11,F12
B-F13,F14
B-F15,F16
A-G1,G2
A-G3,G4
A-G9,G10
B-G11,G12
B-G17,G18

Table 5. List of kinases detected by Human Phospho-kinase Array. The table
includes the phosphorylation site of each protein as well as the coordinates where each
kinase is located within the array. Kinases highlighted in yellow are components of the
AKT/mTOR pathway. Kinases in green can also regulate mTOR inactivation.
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Human Phospho –Kinase Array

Figure 28. Phosphorylation levels of the components of AKT/mTOR pathway decreases
after GCB treatment in LM7 cells. Cells were treated with GCB for 72 hrs and cell lysates
were analyzed using the Human phospho-kinase array. The phosphorylation levels of AKT,
mTOR, PRAS40 and p70S6K were evaluated. Densitometry was performed and the values
were graphed as relative fold change of phospho-protein levels.
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Human Phospho –Kinase Array

Figure 29. Phosphorylation levels of the components of AKT/mTOR pathway decreases
after GCB treatment in CCH-OS-D cells. Cells were treated with GCB for 48 hrs and cell
lysates were analyzed using the Human phospho-kinase array. The phosphorylation levels of
AKT, mTOR, PRAS40 and p70S6K were evaluated. Densitometry was performed and the
values were graphed as relative fold change of phospho-protein levels.
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Effect of GCB treatment on the phosphorylation of JNK, AMPK and ERK
As previously discussed, it has been reported that induction of autophagy
can also be regulated by other pathways. Activation of other kinases such as JNK,
ERK and AMPK, result in mTOR inactivation and autophagy induction [26].
From the Human Phospho-Kinase it was observed that p-ERK levels
decreased in GCB-treated cells when compared to untreated cells. Expression
levels of both p-AMPK isoforms (AMPKα1 and AMPKα2) did not change when
comparing GCB treated cells to control cells. Similar results were obtained for pJNK expression levels. Together, modification in the phosphorylation of JNK, AMPK
and ERK was not observed after GCB treatment, thereby suggesting specificity of
the AKT/mTOR pathway as a potential molecular mechanism involved in GCBinduced autophagy.
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Figure 30. Phosphorylation status of other commonly associated kinases in
the regulation of mTOR. LM7 cells were treated with GCB for 72 hrs and cell
lysates were analyzed using the Human phospho-kinase array. The phosphorylation
levels of JNK, AMPK and ERK were evaluated. Densitometry was performed and
the values were graphed as Relative fold change of phospho-protein levels.
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Summary:
AKT/mTOR is the major regulatory pathway by which the process of
autophagy is inhibited. Previous studies have demonstrated that interruption of this
pathway leads to autophagy induction. To investigate if this pathway is involved in
GCB-induced

autophagy,

we

measured

the

phosphorylation

of

important

components of this pathway.
Activation of mTOR mostly depends on the activity of AKT. In accordance
with our hypothesis, results demonstrated that GCB treatment decreases
phosphorylation of AKT and mTOR, while the non-phosphorylated form of each
protein did not change after treatment. To confirm these results, we utilized a
Human Phospho-Kinase Antibody Array. Consistent with the results obtained by
western blot, the phosphorylation status of both AKT and mTOR was decreased
after GCB treatment. We also found that GCB de-phosphorylates PRAS40, an
important substrate of AKT and mTOR binding protein of the mTORC1 complex
[76]. Furthermore, phosphorylation of p70S6K, a downstream target of mTOR,
significantly decreased following GCB treatment. Our results demonstrate that GCB
acts on different targets of the AKT/mTOR pathway such as AKT, mTOR, PRAS40
and p70S6K. Taken together, these results strongly suggest that AKT/mTOR
pathway is involved in the induction of autophagy.
mTOR activity can also be mediated by JNK, ERK and AMPK. However, in
the LM7 cells, the phosphorylation of these kinases, was not affected following
treatment. Thus, these results indicate that GCB induces autophagy in OS cells by
a mechanism that involves the inhibition of AKT/mTOR signaling pathway.
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Chapter 6. The role of autophagy on the sensitivity of OS cells to GCB
treatment
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Rationale and Aims:
A number of studies have demonstrated that the role of chemotherapyinduced autophagy is associated with cell survival and that inhibition of autophagy
can sensitize cancer cells to chemotherapy as well as increase the therapeutic
efficacy of certain drugs [42, 74].
Since GCB induces autophagy in OS, as demonstrated in chapter 5, the aim
of this chapter is to determine whether autophagy plays a cytoprotective role in OS.
For this purpose, we inhibited autophagy using two different approaches. First we
used the pharmacologic inhibitor, Hydroxychloroquine (HCQ), which blocks the
fusion between the autophagosomes and lysosomes [42]. We examined the effect
of HCQ-induced autophagy inhibition on GCB-induced cytotoxicity in the LM7,
K7M3, CCH-OS-D and MG63 cells.
Many pharmacologic inhibitors are non-specific [78]. Therefore, we also used
shRNA to genetically inhibit the expression of ATG5 and Beclin, two essential
autophagy genes. The effect of ATG5 silencing was evaluated in K7M3 and CCHOS-D cells, while the effect of Beclin silencing was evaluated in K7M3, LM7 and
CCH-OS-D cells.
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Results
Effect of pharmacologic inhibition of autophagy in combination with
Gemcitabine treatment
In order to determine the role of GCB-induced autophagy in OS, as either cell
survival or enhanced cell death, we inhibited thea autophagy using two different
approaches.

First

studies

were

performed

with

the

autophagy

inhibitor

Hydroxychloroquine (HCQ). HCQ is an FDA approved drug for the treatment of
autoimmune disorders, as well as malaria [50]. It prevents the fusion of the
autophagosome with the lysosome by changing the pH of the lysosomes. As
expected, western blot analysis showed an accumulation of LC3II followed by HCQ
treatment, confirming the inhibition of the lysosome- autophagasome fusion which
leads to blockade of LC3 degradation (Figure 31).
As shown in figures 32-35, HCQ alone had no significant cytotoxic effect.
However, pretreatment of LM7 cells with HCQ resulted in increased cell sensitivity
to GCB as demonstrated by a decrease in cell viability (46%) in the combination
treatment group, compared to cells treated with GCB alone (64 %). On the contrary,
combination treatment of HCQ with GCB in the K7M3 and CCH-OS-D cells
significantly decreased OS cells sensitivity to GCB. Viability of K7M3 OS cells
treated with the combination therapy was 39% and 24% in the GCB group. In the
CCH-OS-D cells the viability in the combination group was 78% vs 54% in the GCB
treatment alone. Inhibition of autophagy in the MG63 did not cause any effect in cell
viability (71% vs 74%).
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We further assessed if decreased or increased in sensitivity of these OS cells
to GCB correlated with induction of apoptosis. In the LM7 cells, Annexin/PI staining
was used to determine induction of cell death. Combination of HCQ with GCB
increased cell death (15.9%) compared to GCB alone (11.0%), confirming the
increase in sensitivity. In the K7M3, CCH-OS-D and MG63, we assessed the
expression of cleaved caspase 3 as a hallmark of apoptosis. As shown in figures 33
and 34, in K7M3 and CCH-OS-D cells, treated with the combination treatment HCQGCB showed decreased cleaved caspase 3 expression compared to GCB alone. In
contrast, MG63 had no significant change in the expression of cleaved caspase 3 in
the combination group compared to GCB alone.
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MG63
HCQ

24Hrs
Ctrl

48Hrs

15µM

20µM

Ctrl

15µM

6.3

7.3

1.0

6.7

20µM

LC3I
LC3II
Actin
1.0

8.9

Figure 31. Accumulation of LC3II after HCQ treatment. Cells were treated
with 15 or 20 µM of HCQ for up to 72 hrs then lysed using RIPA buffer. Western
blot analysis was performed using antibodies for LC3. Actin was used as a
loading control.
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Figure 32. Pharmacologic inhibition of autophagy increased the sensitivity of
LM7 OS cells to GCB. (A) LM7 cells were pretreated with HCQ for 30 minutes
followed by GCB treatment for 48Hrs. Cell viability was measured by trypan blue.
(B) Following the corresponding treatment, cell death was determined using double
staining with PI and Annexin V.
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Figure 33. Pharmacologic inhibition of autophagy decreased the sensitivity of
K7M3 OS cells to GCB. (A) K7M3 cells were pretreated with HCQ for 30 minutes
followed by GCB treatment for 48 hrs. Cell viability was measured by trypan blue.
(B) Western Blot analysis was used to detect cleaved caspase 3.
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Figure 34. Pharmacologic inhibition of autophagy decreased the sensitivity of
CCH-OS-D OS cells to GCB. (A) CCH-OS-D cells were pretreated with HCQ for 30
minutes followed by GCB treatment for 48 hrs. Cell viability was measured by
trypan blue. (B) Western Blot analysis was used to detect cleaved caspase 3.
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Figure 35. Pharmacologic inhibition of autophagy has no impact in the
sensitivity of MG63 OS cells to GCB. (A) MG63 cells were pretreated with HCQ
for 30 minutes followed by GCB treatment for 48 hrs. Cell viability was measured by
trypan blue. (B) Western Blot analysis was used to detect cleaved caspase 3.
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The effect of ATG5 silencing in the viability of OS cells to GCB.
Because HCQ has a wide range of non-specific effects, we decided to
confirm the results obtained with HCQ by genetically inhibiting autophagy [78].
ATGs are involved in autophagy regulation and are essential for autophagy
activation. Therefore, additional studies were performed in the K7M3 and CCH-OSD using shRNA against ATG5. ATG5 is part of an important complex with ATG12,
essential for the autophagosome formation [20]. As shown in figures 36 and 37, we
confirmed ATG5 was stably suppressed. To determine if the knockdown of ATG5
was sufficient to block autophagy, conversion of LC3 was monitored by western
blot. Indeed, the cells with ATG5 inhibition had a decreased conversion of LC3 to
LC3II compared to the control.
Down-regulation of ATG5 decreased the sensitivity of K7M3 cells to GCB as
demonstrated in Figure 36. Viability of shATG5-K7M3 treated with GCB was 57%,
which is significantly higher than sh-K7M3 control treated cells at 26%. Similarly,
ShATG5-CCH-OS-D GCB treated cells were also less sensitive to the drug with an
80% viability when compared to sh-CCH-OS-D control treated cells at 54%.

96

A

B

*

Figure 36. Genetic silencing of ATG5 decreased the sensitivity of K7M3 OS
cells to GCB. (A) K7M3 cells were transfected with ATG5 plasmid or with an empty
control vector. Down-regulation of ATG5 and LC3 expression was evaluated by
western blot analysis. (B) K7M3 control cells and shRNA K7M3 cells were treated
with GCB during 48 hrs. Cell viability was detected by trypan blue.
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Figure 37. Genetic silencing of ATG5 decreased the sensitivity of CCH-OS-D
OS cell to GCB. (A) CCH-OS-D cells were transfected with ATG5 plasmid or with
an empty control vector. Downregulation of ATG5 and LC3 expression was
evaluated by western blot analysis. (B) CCH-OS-D control cells and shRNA CCHOS-D cells were treated with GCB for 48 hrs. Cell viability was detected by rrypan
Blue.
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The effect of Beclin silencing in the viability of OS cells to GCB.
Beclin is important for the induction of autophagy as part of the Vps34
complex [20]. As mentioned before, Beclin expression was increased after GCB
treatment. These results led us to investigate if Beclin knockdown would also have
an effect in OS cells sensitivity after treatment with GCB. First, we demonstrated
that Beclin inhibition resulted in decreased LC3I/LC3II conversion.
Experimental data from the Beclin suppressed cells displayed an identical
outcome as with the pharmacologic inhibition by HCQ. That is, a significant
decrease in viability was observed in GCB treated shBECN-LM7 cells with a 32% vs
55% control GCB sh-LM7. In contrast, viability of GCB treated shBECN-K7M3 cells
was higher (43%) than control GCB sh-K7M3 (28%), while viability of GCB treated
shBECN-CCH-OS-D cells was also higher at 57% when compared to control GCB
sh-CCH-OS-D at 28%.

Figure 38. Genetic silencing of Beclin in LM7 CCH-OS-D OS and K7M3 cells.
Cells were transfected with Beclin plasmid or with an empty control vector.
Downregulation of Beclin and LC3 expression was evaluated by western blot
analysis.
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Figure 39. Genetic inhibition of Beclin modulates the sensitivity of LM7, CCHOS-D and K7M3 to GCB. Cells were transfected with Beclin plasmid or with an
empty control vector. Control cells and shRNA cells were treated with GCB for 48 or
72 hrs. Cell viability was detected by trypan blue.
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Summary
While several studies have demonstrated both a cytoprotective and cytotoxic
role of autophagy in cancer, the role of autophagy in OS is still unknown. The
previous observations that GCB induces autophagy in OS cells, led us to examine if
inhibition of autophagy can affect the sensitivity of OS cells to GCB treatment. In
order to answer this question we used two different methods to inhibit autophagy.
Specifically, we used the pharmacologic inhibitor HCQ and genetic inhibition of
ATG5 and Beclin.
In the present study, we showed that HCQ did not have any cytotoxic effect
in OS cells. Inhibition of autophagy in LM7 cells treated with GCB, resulted in a
decrease in cell viability. These results indicate that autophagy regulates the
sensitivity of LM7 OS cells and serves as an induced pro-survival cell mechanism.
Increase in cell death following autophagy inhibition was confirmed by AnnexinV/PI
staining. Conversely, when autophagy was inhibited in K7M3 and CCH-OS-Dtreated with GCB, there was a significant increase in cell viability, supporting the
concept of autophagy as an induced cell-death mechanism. The analysis of the
presence of cleaved caspase 3 in K7M3 and CCH-OS-D revealed a significant
decrease in cell death after inhibition of autophagy. Inhibition of autophagy in MG63
cells did not exert any effect on their sensitivity to GCB treatment as confirmed by
no change in cleaved caspase 3.
Gewirtz et al, have described a type of autophagy termed “Non-protective
autophagy”. This type of autophagy is induced in cancer cells but its inhibition or
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induction do not affect the sensitivity of the cells. Therefore, it is possible that in the
MG63 cells, autophagy is just a “bystander” [31, 79].
To further confirm the pharmacologic results, we used shRNA to knockdown
ATG5 and Beclin. First we demonstrated that inhibition of ATG5 and Beclin,
impaired the process of autophagy as indicated by decreased conversion of
LC3I/LC3II. Consistent with the HCQ results, we demonstrated by the cell viability
assay that ShRNA-transfected cells against ATG5 and Beclin, in combination with
GCB treatment have an opposing effect on the sensitivity of OS cells to GCB.
These results confirm the existence of the dual role of autophagy in response to
chemotherapy in the same type of cancer.
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Table 6 Summary of autophagy roles and markers for each cell line.

Type of Cell

Mouse

Mouse

Human

Human

Human

Cell Line

K7M3

DLM8

LM7

CCH-OS-D

MG63

Effect of GCB
on Beclin
expression
Effect of GCB
on LC3I to LC3II
Ratio

Effect of GCB
on p62

Effect of GCB
on AVOs
Effect of GCB
on
Autophagosome
Formation
Effect of
autophagy
inhibition in
sensitivity of
cells

No

No

Data

Data

No
Data

No
Data

No
Data

No effect
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Chapter 7. HSP27 as a potential factor that regulates the fate of autophagy in
OS cells
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Rationale and aim
The determining factors that distinguish between the cytoprotective and
cytotoxic roles of autophagy remain a fundamental question in the field of
autophagy. The human phospho- kinase array utilized in chapter 6 encompassed
many kinases including Heat shock proteins. Heat shock proteins are proteins
whose expression is increase when cells are exposed to high temperatures and
other types of stress. Heath shock protein B1 (also known as HSP27) is a
chaperone molecule involved in different processes such as unfolding of proteins
and resistance to chemotherapy [80]. It is highly expressed in different types of
cancer including OS [81, 82]. Studies have shown that its expression correlates with
OS lung metastasis [83]. Increased phosphorylated HSP27 has also been shown to
be involved in the resistance of pancreatic cancer cells to GCB [80, 82]. We
demonstrated that autophagy can either increase or decrease the sensitivity of OS
cells to GCB. However, the mechanism that regulates this dual role of autophagy
remains undefined. Here, we hypothesized that HSP27 may be an important factor
that regulates the fate of autophagy in OS cells.
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Results
Phosphorylation status of HSP27 in OS cells after GCB treatment
We used the human phospho-kinase array to test the phosphorylation status
of HSP27 in CCH-OS-D and LM7 OS cells. Results demonstrated that following
GCB treatment there is a clear increase in the levels of p-HSP27 in treated LM7 OS
cells, while decreased levels were observed CCH-OS-D cells (Figure 40 A) as
compared to their respective untreated control cells. Many of the functions of
HSP27 are regulated by change in phosphorylation, including inhibition of apoptosis
[81]. Based on this, we decided to evaluate the protein expression levels of pHSP27 at Ser 78/82 in a panel of OS cells, including CCH-OS-D, K7M3 and LM7
OS cells following treatment with 1 or 5 µM of GCB. As shown in figure 40 B,
protein levels of p-HSP27 at Ser78/82 is decreased in CCH-OS-D and K7M3, while
there is no change in MG63. Surprisingly, we found that the phosphorylation status
of HSP27 correlates with the role of autophagy in the different OS cells (Table 7).
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A

B

Figure 40. Phosphorylation status of HSP27 in OS cells. (A) CCH-OS-D
and LM7 cells were treated during 48 and 72 hrs, respectively. Cells were then
analyzed by human phospho-kinase array. (B)K7M3, CCH-OS-D and MG63 cells
were treated with indicated doses of GCB. Cells were collected and lysate with
RIPA buffer. Western blot analysis was performed using specific antibody for pHSP27 (Ser78/82). Actin was used as a loading control.
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Phosphorylation status of HSP27 correlates with the role of autophagy in
K7M3 OS cells treated with 9-NC or GCB
In order to determine if this correlation of HSP27 and the protective effect of
autophagy in response to GCB is relevant to other chemotherapeutic treatment
agents, we decided to compare the levels of p-HSP27 in the K7M3 cells treated with
9- nitro- camptothecin (9-NC) or GCB. Our laboratory has previously demonstrated
that inhibition of autophagy through the genetic inhibition of ATG5 in 9-NC K7M3treated cells resulted in a significant decrease in cell viability, suggesting autophagy
as a cell survival inducing mechanism [84]. As shown in figure 41, HSP27 is
dephosphorylated in sh-ATG5 K7M3 cells treated with GCB, while in the sh-ATG5
K7M3 cells treated with 9NC, p-HSP27 levels increased. These results suggest that
the phosphorylation status of HSP27 correlates with the role of autophagy.

A

B

Figure 41. Status of HSP27 phosphorylation after GCB and 9NC treatment in
K7M3 cells. (A) ShATG5-K7M3 cells were treated with different doses of GCB or
9NC and cell viability was performed. (B) K7M3 cells were lysed with RIPA buffer
and subjected to western blot analysis by using a specific antibody for p-HSP27.
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Phosphorylation of p38 MAPK after GCB treatment
We decided to evaluate the signaling pathway involved in HSP27
phosphorylation.

HSP27

has

been

identified

as

a

downstream

of

the

serine/threonine kinase, p38 MAPK [80]. Therefore, we investigated whether p38
MAPK was involved in the phosphorylation of HSP27 in GCB treated CCH-OS-D
and LM7 cells. Our preliminary results displayed that compared to control cells, no
change in p38 MAPK protein levels was detected in CCH-OS-D or LM7 cells after
GCB treatment, suggesting that p38 MAPK may not be involved in the
phosphorylation of HSP27 in OS.

Figure 42. Phosphorylation of p38 after GCB treatment. CCH-OS-D
and LM7 cells were treated with GCB during 48 and 72 hrs, respectively. Cell
lysates were analyzed using the Human phospho kinase array. The phosphorylation
levels of p38-MAPK were evaluated.
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Expression of HSP27 in LM7 knockdown cells
In order to explore if HSP27 has any effect in the context of GCB-induced
autophagy in OS cells, we used shRNA to create LM7 OS cells with deplete
expression of HSP27. Efficacy of HSP27 depletion was confirmed by western blot
analysis. Further studies are ongoing to confirm the potential role of HSP27 in GCBinduced autophagy in OS cells.

Figure 43. HSP27 knockdown decreases autophagy in LM7 OS cells. LM7 cells
were transfected with HSP27 shRNA. Cells were lysed using RIPA buffer and
subjected to Western blot analysis using antibodies specific for HSP27. Actin was
used as a loading control.
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8.3 Summary
On this chapter we demonstrated that there is a visible decrease of HSP27
phosphorylation levels in CCH-OS-D and K7M3 after treatment with GCB. The
contrary was found for LM7 cells; HSP27 phosphorylation levels increased after
treatment with GCB.
Analysis of the phosphorylation of HSP27 and the role of autophagy in each
OS cell line demonstrated that there is a correlation between the phosphorylation
status of HSP27 and the role of autophagy (See Table 7). Specifically,
phosphorylation of HSP27 correlates with the cytoprotective role of autophagy while
in the cells where autophagy have a cytotoxic role, p-HSP27 levels are low.
This data provides information to understand that HSP27 may be a potential
regulator in defining the outcome of GCB-induced autophagy in OS. Regulation of
HSP27 phosphorylation and the autophagic pathway may help to develop novel
therapeutic strategies for OS treatment in the future.
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Table 7. Summary of Results. The phosphorylation status of HSP27 correlates
with the role of autophagy in OS cells.

Cell Line

P-HSP27
Expression
After GCB treatment

Role of Autophagy

LM7

Increase

Cell survival

CCH-OS-D

Decrease

Cell death

K7M3

Decrease

Cell death

MG63

No change

No effect
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Chapter 8. Discussion and Future directions
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Discussion
OS remains a difficult disease to treat with 30-35% of patients dying of lung
metastasis. New better targeted therapies are needed. Studies from our group has
previously demonstrated that the nucleoside analogue, GCB, has a significant
therapeutic effect against OS lung metastasis. However, a population of cells fails to
respond, due to acquired resistance. Better understanding of the molecular
mechanisms underlying OS resistance to GCB is necessary.
Autophagy has been described as a potential mechanism that may help
cancer cells to survive under stressful conditions, such as in the presence of
chemotherapy.

The role of GCB-induced cytoprotective autophagy has been

studied in various cancer models [68, 85]. However, there is no report on the
relevance of autophagy in the sensitivity of OS cells to GCB treatment.
To extend our understanding of the potential role of autophagy in OS, we
established three objectives: investigate the induction of autophagy after GCB
treatment in OS cells; 2) elucidate the potential mechanism by which GCB induces
autophagy in OS; 3) determine the role of autophagy in OS cell sensitivity to GCB.
To accomplish these objectives, we conducted a series of studies using different
types of OS cells and mouse models. In the current study, for the first time, we
demonstrated that GCB can induce both cytoprotective and cytotoxic autophagy in
OS cells through a mechanism that involve inactivation of the AKT/mTOR signaling
pathway and when HSP27 is induced inhibition of autophagy will increase sensitivity
to GCB.
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We began by evaluating the sensitivity of a panel of OS cells to GCB. In
accordance with previous studies from our lab, we found that GCB exerts a
cytotoxic effect in OS cells, suggested by a significant decrease in cell viability and
induction of cleaved caspase 3 [18, 19]. K7M3 cells were the most sensitive cell line
followed by the CCH-OS-D and LM7, respectively. However, it was observed that
after 72 hrs treatment with GCB some cells remain with a viable, suggesting that a
population of cells were less sensitive to GCB treatment. We proposed that
autophagy was induced as a mechanism of resistance.
GCB-induced autophagy was demonstrated in a panel of 5 OS cell lines
Through western blot analysis, we observed an increase in Beclin expression and
conversion of LC3I to LC3II. We also observed expression of p62 decreased in
treated cells when compared to control cells. Immunofluorescence staining revealed
increased formation of acidic vesicles in all treated cell lines. Electron microscopy
was used to visualize and verify the nature of the autophagic vacuoles, to verify if in
fact they had the characteristic double membrane of autophagic vesicular
organelles. All these consistent results allows us to conclude that GCB induces
autophagy is OS cells after treatment.
Two mouse OS mouse models were used to verify autophagy induction in
vivo. Using IHC staining of LC3 and Beclin, the expression of these two autophagy
markers was evaluated after aerosol GCB treatment. We found that indeed both
markers were upregulated in treated mice when compared to control. Electron
microscopy revealed higher number of double membrane autophagic vacuoles in
the treated group. These results are consistent with the in vitro data allowing us to
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conclude autophagy induction in OS after GCB treatment. These results are also in
accordance with published research concluding GCB induces autophagy in
pancreatic and breast cancer cells [58, 59]. This is therefore the first study to prove
that GCB treatment induces autophagy in OS both in vitro and in vivo.
Autophagy activation is associated with the downregulation of the
AKT/mTOR pathway [75]. Western blot analysis revealed down-regulation of
phosphorylated AKT (S473) and mTOR (S2448) by GCB treatment; total AKT and
mTOR levels remained unchanged. Additionally, a human phospho-kinase array
was used to verify western blot results and to check for other kinases that may have
some involvement in the autophagy induction pathway after treatment with GCB.
Results revealed GCB induced de-phosphorylation of AKT at S473 and mTOR at
Ser2448, which is one of the most important residues for mTOR activity [77].
Additionally, as revealed by the human phospho-kinase array; GCB decreased
phosphorylation of two mTOR related targets: PRAS40 and P70S6K. No changes
were observed in phosphorylation of AMPK, JNK or ERK; common mTOR
inhibitors. Taken together, these results suggest that AKT/mTOR pathway is
involved in the induction of autophagy by GCB in OS cells. These results are
consistent with Le et al., who demonstrated that Dasatinib-induced autophagy in
ovarian cancer cells depends on the inhibition of the AKT and mTOR pathway [72].
In addition, Wang et al., reported that Quercetin induces cytoprotective autophagy
in gastric cancer cells and underscored the involvement of the AKT/mTOR pathway
[69].
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Regarding the role of autophagy in OS; several studies have proposed that
autophagy can either promote cell death or cell survival. We initially hypothesized
that GCB-induced autophagy decreased the sensitivity of OS cells to GCB.
Utilizing pharmacologic and genetic inhibition of autophagy, we aimed to
study the role of autophagy in OS cells after treatment with GCB. Interestingly,
significant decrease in cell viability was observed in LM7 cells treated with GCB
after autophagy had been inhibited using HCQ, ATG5 or Beclin shRNA. These
results suggest a cytoprotective role in LM7 cells which is consistent with published
studies such as: paclitaxel treatment of Saos-2 osteosarcoma cells [2] and
Everolimus treatment in Mantle cell lymphoma [86].
However, either pharmacologic or genetic inhibition of autophagy in the
K7M3 and CCH-OS-D significantly decreased the sensitivity of these cells to GCB
as demonstrated by an increase in cell viability and decrease in expression of
cleaved caspase 3. These results confirm that autophagy induction can have dual
roles, both cytoprotective and cytotoxic in OS. These results suggest that GCBinduced autophagy has a cytoprotective role in the LM7 cells whereas GCB-induced
autophagy in CCH-OS-D and K7M3 enhances tumor cell death.
Even though the dual role of autophagy in cancer has been reported, to our
knowledge this is the first study demonstrating that GCB can induces both
cytoprotective and cytotoxic autophagy in OS. These results are consistent with the
recently published work by Hollomon and coworkers where they showed that
Camptothecin (CPT) induces autophagy in DLM8 and K7M3 mouse OS cells and
that inhibition of autophagy has an opposite effect on CPT-induced cytotoxicity
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within OS cells [84]. In addition, Gewirtz et al., have also demonstrated the
induction of both cytoprotective and cytotoxic autophagy in breast cancer cells after
radiation treatment [66].
Although the factor that distinguishes between the cytoprotective or cytotoxic
role of autophagy is unknown, we proposed HSP27 as a potential factor for the
regulation of GCB-induced autophagy in OS cells. We demonstrated that following
GCB treatment there is a clear increase in the levels of p-HSP27 in the treated LM7
OS cells, while decreased levels were observed in the CCH-OS-D and K7M3
treated OS cells. However, in MG63 cells, there was no significant difference in pHSP27 between treated and un-treated cells. Interestingly, on K7M3 and CCH-OSD cells, the role of autophagy was cytotoxic, whereas in the LM7 cells the role was
found to be cytoprotective. These results suggest that phosphorylation of HSP27
correlates with autophagy as a mechanism of cellular resistance.
In contrast to Nakashima et al., who previously reported that p38 MAPK is
involved in phosphorylation of HSP27 in GCB-treated pancreatic cancer cells, our
results indicate that after GCB treatment there was no change in the
phosphorylation of p38, suggesting that phosphorylation of HSP27 is regulated by
other kinase. More detailed studies are necessary to underscore the potential role
of HSP27 in the regulation of autophagy.
In conclusion, we have demonstrated that GCB can induce both
cytoprotective and cytotoxic autophagy in OS cells. In addition, we also
demonstrated the involvement of AKT/mTOR pathway in GCB-induced autophagy
and HSP27 as the potential factor that regulates the fate of autophagy. Recently,
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there has been significant enthusiasm around the modulation of autophagy as a
novel strategy for cancer treatment in multiple tumor types. Current clinical trials
involving combination of chemotherapeutic agents with autophagy inhibitors such as
HCQ are ongoing. However, the autophagy paradox remains. The role of
autophagy, cytoprotective or cytotoxic, should be established on the specific
intended target/ treatment combination. There is still a need for better
understanding of the molecular pathways that govern the process of autophagy and
the possible outcome of the cells. While autophagy can be induced in OS, the role
of autophagy in treatment response and its potential as therapeutic target through
either upregulation or inhibition of the process requires further investigation.

119

Figure 44. Schematic of proposed model. After GCB treatment there is a decrease
in the phosphorylation of AKT and mTOR which leads to the induction of autophagy.
The process of autophagy is suggested by activation of Beclin, degradation of p62
and conversion of LC3I/LC3II. The role of autophagy is cell dependent leading to a
decreased in sensitivity of LM7 cells OS to GCB and an increase sensitivity of CCHOS-D and K7M3. HSP27 is proposed as a potential modulator of the fate of
autophagy.
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Future Directions
Determination of the role of autophagy in vivo
We have demonstrated induction of autophagy in K7M3 and LM7 OS lung
metastasis followed aerosol GCB treatment. However the role of GCB-induced
autophagy in OS lung metastasis is unknown. Therefore, a critical aspect for further
investigation would be to evaluate the role of autophagy in the sensitivity of OS cells
in vivo.
In chapter 6, we demonstrated that inhibition of autophagy using the
pharmacologic inhibitor HCQ leads to either increased or decreased OS cell
sensitivity to GCB in vitro. Therefore, using OS mouse models, the therapeutic
effect of GCB can be evaluated when used alone and in combination with HCQ.
The therapeutic effect can be measured by wet-lung weight and number of macro
and micro-metastasis in the different mice populations, while evidence of autophagy
will be determined by the analysis of tissue samples using immunohistochemistry
and electron microscopy.
To inhibit autophagy more specifically at the molecular level, we can target
specific proteins that are required for the process of autophagy. Some proteins to
be studied include: Beclin and ATG5. OS cells will be transfected by means of
shRNA to suppress the expression of the intended target proteins. shRNA
transfected OS cells will be injected I.V. into the tail vein. Evidence of lung
metastases will be determined. Therapy with aerosol GCB will be given and
therapeutic effect and autophagy induction will be measured as previously
described.
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Mechanistic studies
As shown in chapter 5, we have demonstrated a decrease in the
phosphorylation of key components of the AKT/mTOR pathway suggesting a
correlation between the inactivation of this pathway and induction of autophagy.
However, studies to confirm that autophagy induction is due to mTOR inhibition are
needed. To further confirm this, Rapamycin, an mTOR inhibitor, will be used to
inactivate mTOR. We will expect to see that the combination treatment of
Rapamycin and GCB will suppress the activation of mTOR and lead to an
accumulation of LC3, indicating induction of autophagy. In addition, the effect of this
combination on the sensitivity of OS cells can be measured by cell viability and
induction of cell death. We will expect to see that inhibition of mTOR by Rapamycin
will increase the sensitivity of LM7 cells and decrease the sensitivity of CCH-OS-D
and K7M3, confirming that GCB induces autophagy through inhibition of the
AKT/mTOR pathway.
Another important question that remains is to determine how GCB treatment
causes a decrease in AKT/mTOR pathway. Since one of the mechanisms of GCB is
to inhibit the function of Ribonucleotide Reductase, the enzyme involved in the
formation of deoxyribonucleotides, we hypothesized that the AKT/mTOR pathway
will be inactivated as a signal to the cells for recycling cellular components
necessary for energy and sustain survival, thus activating autophagy.
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HSP27 as potential factor that regulates the fate of Gemcitabine- induced
autophagy in osteosarcoma
We

have

demonstrated

that

following

treatment

with

GCB

the

phosphorylation status of HSP27 correlates with the role of autophagy. However,
whether HSP27 is involved in the regulation of the role of autophagy is unknown. It
would be beneficial to continue exploring the potential of HSP27 as a candidate
factor that might regulate the observed dual role of autophagy in OS, both on a
cellular and systemic level. Currently, there are no specific HSP27 inhibitors. We
propose to use specific genetic inhibition. We would also determine the sensitivity of
OS cells to GCB after inhibition of HSP27. The information obtained from these
experiments would provide knowledge to design future experiments.
Translational Implications
A fundamental piece of information that needs to be assessed is whether
autophagy is induced in OS tumor specimens following chemotherapy treatment. A
potential approach to address this aim would be to analyze patient samples (pretreatment and primary resection) for autophagy markers, such as LC3, and
expression of HSP27 and to correlate the levels of expression with clinical
outcomes.

Based

on

the

premise

that

autophagy is

a

mechanism

of

chemoresistance and that HSP27 may be a potential factor that regulates the fate of
autophagy in osteosarcoma, we hypothesize that patients with significant induction
of autophagy and high levels of HSP27 will have a poorer response to
chemotherapy, thus worse clinical outcomes. The results of this study will provide
knowledge for using autophagy and HSP27 as a prognostic biomarkers. Further,
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this could potentially serve as the rationale for the use of autophagy inhibitors or
inducers in combination with GCB for future clinical trials.
Another potential future direction will be to assess what are the
transcriptional regulators of autophagy through gene expression profiling. We can
test OS cell lines that have shown the dual role of autophagy (LM7 and CCH-OSD), to better understand which genes are associated with the induction of
cytoprotective or cytotoxic autophagy.
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